

CURRICULUM VITAE**THOMAS N. WIGHT, Ph.D.**

Director, Matrix Biology Program
 Benaroya Research Institute at Virginia Mason
 1201 Ninth Avenue
 Seattle, WA 98101-2795
 Phone: (206) 287-5666
 Fax: (206) 342-6567
 Email: twight@benaroyaresearch.org

RESEARCH INTERESTS

The cell biology and pathology of the extracellular matrix. Specific interests include the role of proteoglycans and associated molecules in tissue structure and function as well as in the regulation of cell phenotype in disease.

EDUCATION

Ph.D.	1972	University of New Hampshire, Durham, NH	Zoology
M.S.	1968	University of New Hampshire, Durham, NH	Zoology
B.A.	1966	University of Maine, Orono, ME	Zoology

POSTGRADUATE TRAINING

1972 - 1974 NIH Postdoctoral Fellow, University of Washington, Seattle, WA

FACULTY POSITIONS AND PROFESSIONAL EXPERIENCE

2019 - present	<u>Affiliate Faculty</u> , UW Medicine Diabetes Institute, University of Washington, Seattle, WA
2016 - present	<u>Member, Scientific Advisory Board</u> , Symic Bio, Emeryville, CA
2009 - present	<u>Chief Executive Officer & President</u> , Matrexa LLC, Seattle, WA
2008 - present	<u>Director and Member</u> , Matrix Biology Program, Benaroya Research Institute at Virginia Mason, Seattle, WA
2007 - 2018	<u>Affiliate Faculty</u> , Diabetes & Obesity Center of Excellence, School of Medicine, University of Washington, Seattle, WA
2004 - 2008	<u>Member</u> , Hope Heart Program, Benaroya Research Institute at Virginia Mason, Seattle, WA
2000 - 2004	<u>Chair, Vascular Biology</u> , The Hope Heart Institute, Seattle, WA
2000 - present	<u>Affiliate Professor of Pathology</u> , Department of Pathology, School of Medicine, University of Washington, Seattle, WA
1988 - 2000	<u>Professor of Pathology</u> , Department of Pathology, School of Medicine, University of Washington, Seattle, WA
1983 - 1988	<u>Associate Professor of Pathology</u> , Department of Pathology, School of Medicine, University of Washington, Seattle, WA
1978 - 1983	<u>Assistant Professor of Pathology</u> , Department of Pathology, School of Medicine, University of Washington, Seattle, WA

1974 - 1978 Assistant Professor of Animal Science, Director of Electron Microscopy,
University of New Hampshire, Durham, NH

HONORS

2019 Honoree, International Society of Hyaluronan Sciences, 2019 Meeting, Cardiff, Wales, UK

2013 Diploma of Honor from the University of Patras, Greece, awarded for significant scientific achievements in the field of matrix pathobiology

2013 International Union of Biochemistry and Molecular Biology (IUBMB) Medal

2006 - Present Elected Council Member, Histochemical Society

2005 - Present Elected Council Member, American Society of Matrix Biology

1990 - Present Fellow, American Heart Association (FAHA)

1981 - 1986 Established Investigator, American Heart Association

1972 - 1974 National Institute of Health Postdoctoral Fellowship

1972 Phi Sigma Outstanding Graduate Student Award

1970 - 1972 New Hampshire Heart Association Predoctoral Fellowship

1966 - 1970 National Defense Education Act Predoctoral Fellowship

PROFESSIONAL MEMBERSHIPS

American Society for Investigative Pathology (since 1990)

American Association for the Advancement of Science (since 1995)

The Histochemical Society (since 1995)

American Society for Matrix Biology (since 2000)

Fellow, American Heart Association (Council on Arteriosclerosis) (since 2001)

International Society for Hyaluronan Sciences, Founding Member (since 2003)

North American Vascular Biology Organization (NAVBO) (since 2007)

Network for Pancreatic Organ Donors with Diabetes (nPOD) (since 2010)

American Society of Biochemistry and Molecular Biology (ASBMB) (since 2014)

SPECIAL NATIONAL & INTERNATIONAL RESPONSIBILITIES

2016 - present Editorial Board: *Frontiers in Immunology*

2015 - present Editorial Board: *Matrix Biology*

2014 Ad Hoc Study Section Member, NHLBI, "Blood and Vascular Systems Response to Sepsis (R01)"

2013 - present Advisory Board Member, Canada Institute of Health Research Multi-institutional Grant Application, "Hyaluronan (HA):protein interactions in chronic inflammation and disease"

2013 Ad Hoc Member, NIDCR Board of Scientific Counselors

2013 - present Member, External Advisory Board, NHLBI Cleveland Clinic Program of Excellence in Glycoscience (CC-PEG)

2013 - 2015 Associate Editor Board: *Matrix Biology*

2013 - present Member, External Advisory Board, P50 Clinical Research Center, "Experimental and Clinical Studies of the Presbycusis," Medical University of South Carolina

2012 - 2013 Scientific Organizing Committee for the 8th International Proteoglycan Conference, Frankfurt, Germany, August 2013

2011 - present	Editorial Board: <i>Journal of Cellular Biochemistry</i>
2011 - present	Editorial Board: <i>Current Angiogenesis</i>
2007 - 2012	Board of Trustees, International Society of Hyaluronan Sciences (ISHAS)
2009 - present	Member, Japan Society for the Promotion of Science (International Training Program – ITP)
2008	Ad Hoc Member of Intercellular Interactions Study Section, NIH
2008 - present	Council Liaison between the North American Vascular Biology Organization & the Arteriosclerosis, Thrombosis, and Vascular Biology Council
2007 - 2008	Chair, Proteoglycans, 2008 Gordon Research Conference
2006 - 2009	Program Committee for the Annual Meeting of the American Heart Association
2005 - 2012	Board Member, The Hope Heart Institute
2005 - 2012	Editorial Board: <i>Matrix Biology</i>
2005 - present	Editorial Board: <i>Current Cardiology Reviews</i>
2004 - present	Editorial Board: <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i>
1998 - present	Editorial Board (Assoc. Ed.): <i>Journal of Histochemistry & Cytochemistry</i>
2001	Member, Board of Scientific Counselors, Craniofacial and Skeletal Diseases Branch (NIDCR, NIH)
1999 - 2003	Study Section Member for Research Awards, American Heart Association
1998 - 2001	Editorial Board: <i>Arteriosclerosis, Thrombosis and Vascular Biology</i>
1994 - 2000	Editorial Board: <i>Glycoconjugate Journal</i>
1990 - 2001	Editorial Board: <i>Archives of Biochemistry and Biophysics</i>
1986 - 1989	Pathobiochemistry Study Section (Regular Member)
1982 - 1986	Ad Hoc Member of Pathobiochemistry Study Section, NIH
1980 - present	Ad Hoc Reviewer, National Science Foundation, Veterans Administration
1978 - present	Ad Hoc Reviewer (minimum of 5 papers/year) <i>American Journal of Pathology; Atherosclerosis; Biochemistry; Circulation; Circulation Research; Journal of Biological Chemistry</i>

DEPARTMENT AND UNIVERSITY RESPONSIBILITIES

2016 - present	Appointments and Promotions Committee, Benaroya Research Institute
2008	Committee Member, Office of Research Integrity, UW School of Medicine
1997 - 2000	Appointments and Promotion Committee, UW School of Medicine
1991 - 1993	Associate Director, Interdisciplinary Molecular and Cellular Biology Program, UW
1990 - 2000	Appointments and Promotion Committee, Department of Pathology, UW
1986 - 1992	Cell Biology Training Program Planning Committee, UW
1986 - 1990	Executive Subcommittee of the Admissions Committee, UW
1983 - 1991	Co-Director, Graduate Program, Department of Pathology, UW
1983 - 1990	Admissions Committee, UW School of Medicine
1978 - 1987	Director, Electron Microscopy Laboratory, UW School of Medicine

TEACHING EXPERIENCE

University of Washington

2006 - 2009	Lecturer - "Atherosclerosis and Myocardial Infarction," Path 511
1984 - present	Lecturer - "Human Pathology" Path 444
1983 - present	Lecturer - Graduate Student Proseminar, Path 501
1978 - present	Supervisor - Medical students, undergraduates, graduate students Research Lab rotations, Path 551
1978 - present	Served on 5 Master of Science Thesis Committees, 36 Doctoral Thesis Committees
1993 - 1999	Lecturer - "Molecular and Cell Biology" Conjoint 503
1991 - 1994	Course Director / Lecturer - Molecular and Cell Biology" Conjoint 503,504,505
1991 - 1994	Course Director - Graduate Student Seminar "Molecular and Cell Biology" Conjoint 514, 515
1991	Preceptor - Health Science Minority Students Research Apprentice Program

University of New Hampshire

1974 - 1978	Course Director / Lecturer	Advanced Cell Biology
1974 - 1978	Course Director / Lecturer	Introduction to Electron Microscopy

PUBLICATIONS

1. Santerre RF, **Wight TN**, Smith SC, Brannigan D. Spontaneous atherosclerosis in pigeons: A model system for studying metabolic parameters associated with atherogenesis. *Am J Pathol.* 67:1-22, 1972. *PMCID: PMC2032587*
2. **Wight TN**, Ross R. Proteoglycans in primate arteries. I. Ultrastructural localization and distribution in the intima. *J Cell Biol.* 67:660-674, 1975.
3. **Wight TN**, Ross R. Proteoglycans in primate arteries. II. Synthesis and secretion of glycosaminoglycans by smooth muscle cells in culture. *J Cell Biol.* 67:675-686, 1975.
4. **Wight TN**. Synthesis and secretion of glycosaminoglycans by primate arterial smooth muscle cells in vitro. In: *The Smooth Muscle of the Artery*. Wolfe S, Werthessen NT, eds, Plenum Press, *Adv Exp Med Biol.* 57:103-110, 1975.
5. **Wight TN**, Cooke PH, Smith SC. An electron microscopic study of pigeon aorta cell cultures. Cytodifferentiation and intracellular lipid accumulation. *Exp Mol Pathol.* 27:1-18, 1977.
6. Perry LL, **Wight TN**, Collins WM, Dunlop WR. Differentiation of progressive versus regressive Rous virus-induced avian sarcomas according to tumor and infiltrating lymphocyte fine structure. *Poultry Sci.* 57:80-84, 1978.
7. Gallagher ET, Harris N, Morin P, **Wight TN**. Effects of carrageenan on chick embryo fibroblasts *in vitro* – A preliminary study. In: *Scanning Electron Microscopy, vol. II*. Becker RP, Johari D, eds, SEM Inc., Chicago, 779-784, 1978.

8. Levine H, **Wight T**, Squires E. Ultrastructure of the corpus luteum of the cycling mare. *Biol Reprod.* 20:492-504, 1979.
9. Hajjar DP, **Wight TN**, Smith SC. Lipid accumulation and ultrastructural change within the aortic wall during early spontaneous atherogenesis. *Am J Pathol.* 100:683-705, 1980. *PMCID: PMC1903566*
10. **Wight TN**. Differences in the synthesis and secretion of sulfate glycosaminoglycans by aorta explant monolayers cultured from atherosclerosis-susceptible and -resistant pigeons. *Am J Pathol.* 101:127-42, 1980. *PMCID: PMC1903581*
11. **Wight TN**. Vessel proteoglycans and thrombogenesis. In: *Progress in Hemostasis and Thrombosis*, vol. 5. Spaet TH, ed, Grune and Stratton Inc., New York, pp. 1-39, 1980.
12. Iozzo RV, Goldes JA, Chen WJ, **Wight TN**. Glycosaminoglycans of pleural mesothelioma: A possible biochemical variant containing chondroitin sulfate. *Cancer.* 48:89-97, 1981.
13. Verdery RB, Nist C, Fijimoto WY, **Wight TN**, Glomset JA. Reversible ultrastructural changes in human fibroblasts grown in hapes buffered MCDB-104 supplemented with human serum. *In Vitro.* 17:956-964, 1981.
14. **Wight TN**. Proteoglycans and atherosclerosis. In: *Diabetes and Atherosclerosis Connection*. Moskowitz J, ed. New York: Juvenile Diabetes Foundation Medical Services Press, 1981.
15. Oohira A, **Wight TN**, McPherson J, Bornstein P. Biochemical and ultrastructural studies of proteoglycan sulfates synthesized by PYS-2, a basement membrane-producing cell line. *J Cell Biol.* 92:357-367, 1982.
16. Iozzo RV, Kushwaha RS, **Wight TN**, Hazzard WR. Cellular and subcellular distribution of ¹²⁵I-labeled very low density lipoproteins in the liver of normal and estrogen-treated rabbits. *Am J Pathol.* 107:6-15, 1982. *PMCID: PMC1915988*
17. Iozzo RV, MacDonald GH, **Wight TN**. Immunoelectron microscopic localization of catalase in human eosinophilic leukocytes. *J Histochem Cytochem.* 30:697-701, 1982.
18. Schmidt RA, Glomset JA, **Wight TN**, Habenicht AJ, Ross R. A study of the influence of mevalonic acid and its metabolites on the morphology of swiss 3T3 cells. *J Cell Biol.* 95:144-153, 1982.
19. Iozzo RV, Bolender RP, **Wight TN**. Proteoglycan changes in the intercellular matrix of human colon carcinoma: an integrated biochemical and stereological analysis. *Lab Invest.* 47:124-138, 1982. (*This paper received the Benjamin Castleman Award for Outstanding paper in the field of human pathology.*)
20. Iozzo RV, **Wight TN**. Isolation and characterization of proteoglycans synthesized by human colon and colon carcinoma. *J Biol Chem.* 257:11135-11144, 1982.
21. Iozzo RV, Marroquin R, **Wight TN**. Analysis of proteoglycans by high-performance liquid chromatography: a rapid micromethod for the separation of proteoglycans from tissue and cell culture. *Anal Biochem.* 126:190-199, 1982.
22. **Wight TN**, Hascall VC. Proteoglycans in primate arteries. III. Characterization of the proteoglycans synthesized by arterial smooth muscle cells in culture. *J Cell Biol.* 96:167-176, 1983.

23. Oohira A, **Wight TN**, Bornstein P. Sulfated proteoglycans synthesized by vascular endothelial cells in culture. *J Biol Chem.* 258:2014-2021, 1983.
24. Martin GM, Ogburn CE, **Wight TN**. Comparative rates of decline in the primary cloning efficiencies of smooth muscle cells from the aging thoracic aorta of two murine species of contrasting maximum lifespan potentials. *Am J Pathol.* 110:236-245, 1983. *PMCID: PMC1916149*
25. Harris-Hooker SA, Gajdusek CM, **Wight TN**, Schwartz SM. Neovascular responses induced by cultured aortic endothelial cells. *J Cell Physiol.* 114:302-310, 1983.
26. Chang Y, Yanagishita M, Hascall VC, **Wight TN**. Proteoglycans synthesized by smooth muscle cells derived from monkey (*Macaca nemestrina*) aorta. *J Biol Chem.* 258:5679-5688, 1983.
27. **Wight TN**, Curwen KD, Litrenta MM, Alonso DR, Minick CR. Effect of endothelium on glycosaminoglycan accumulation in injured rabbit aorta. *Am J Pathol.* 113:156-164, 1983. *PMCID: PMC1916366*
28. Ross R, **Wight TN**, Strandess E, Thiele B. Human atherosclerosis – I. Cell constitution and characteristics of advanced lesions of the superficial femoral artery. *Am J Pathol.* 114:79-93, 1984. *PMCID: PMC1900400*
29. Cliff WJ, **Wight TN**. Microvessels in avian atheroma. In: *Progress in Microcirculation Research II*. Courtice FC, Garlick DG, Perry MA, eds, Committee in Postgraduate Medical Education, University of New South Wales, Sydney, pp. 205-209, 1984.
30. Chen K, **Wight T**. Proteoglycans in arterial smooth muscle cell cultures: an ultrastructural histochemical analysis. *J Histochem Cytochem.* 32:347-357, 1984.
31. Clowes AJ, Clowes MM, Gown AM, **Wight TN**. Localization of a proteoheparan sulfate in rat aorta. *Histochemistry.* 80:379-384, 1984.
32. **Wight TN**, Raugi GJ, Mumby SM, Bornstein P. Light microscopic immunolocalization of thrombospondin in human tissues. *J Histochem Cytochem.* 33:295-302, 1985.
33. Bingel SA, Sande RD, **Wight TN**. Chondrodysplasia in the Alaskan malamute: characterization of proteoglycans dissociatively extracted from dwarf growth plates. *Lab Invest.* 53:479-485, 1985.
34. **Wight TN**. Proteoglycans in pathological conditions: atherosclerosis. *Fed Proc.* 44:381-385, 1985. Review.
35. Singer JW, Keating A, **Wight TN**. The human haematopoietic microenvironment. *Recent Adv Haematol.* 4:1-24, 1985. Review.
36. **Wight TN**, Kinsella MG, Potter-Perigo S. Proteoglycans synthesized and secreted by cultured vascular cells. In: *Extracellular Matrix: Structure and Function*. Reddi AH, ed, *J Cell Biochem.* 26:S8B, Alan Liss, NY, pp. 321-322, 1985.
37. Bryant E, Salk D, **Wight T**. Proteoglycans in the Werner Syndrome and aging: a review and perspective. *Adv Exp Med Biol.* 190:553-565, 1985. Review
38. **Wight TN**, Kinsella MG, Lark MW, Potter-Perigo S. Vascular cell proteoglycans: Evidence for metabolic modulation. *Ciba Found Symp.* 124:241-259, 1986.
39. **Wight TN**, Kinsella MG, Keating A, Singer JW. Proteoglycans in human long-term bone marrow cultures: biochemical and ultrastructural analyses. *Blood.* 67:1333-1343, 1986.

40. Kinsella MG, **Wight TN**. Modulation of sulfated proteoglycan synthesis by bovine aortic endothelial cells during migration. *J Cell Biol.* 102:679-687, 1986.
41. Bingel SA, Sande RD, **Wight TN**. Undersulfated chondroitin sulfate in cartilage from a miniature poodle with spondyloepiphyseal dysplasia. *Connect Tissue Res.* 15:283-302, 1986.
42. Garrigues HJ, Lark MW, Lara S, Hellström I, Hellström KE, **Wight TN**. The melanoma proteoglycan: restricted expression on microspikes, a specific microdomain of the cell surface. *J Cell Biol.* 103:1699-1710, 1986.
43. Kapoor R, Phelps CF, **Wight TN**. Physical properties of chondroitin sulfate/dermatan sulfate proteoglycans from bovine aorta. *Biochem J.* 240:575-583, 1986. *PMCID: PMC1147452*
44. Lark M, **Wight TN**. Modulation of proteoglycan metabolism by aortic smooth muscle cells grown on collagen gels. *Arteriosclerosis.* 6:638-650, 1986.
45. Mar H, Tsukada T, Gown AM, **Wight TN**, Baskin DG. Correlative light and electron microscopic immunocytochemistry on the same section with colloidal gold. *J Histochem Cytochem.* 35:419-425, 1987.
46. Charbord P, Tippens D, **Wight TN**, Gown AM, Singer JW. Stromal cells from human long-term marrow cultures, but not cultured marrow fibroblasts, phagocytose horse serum constituents: studies with a monoclonal antibody that reacts with a species-specific epitope common to multiple horse serum proteins. *Exp Hematol.* 15:72-77, 1987.
47. Singer JW, Charbord P, Keating A, Nemunaitis J, Raugi G, **Wight TN**, Lopez JA, Roth GJ, Dow LW, Fialkow PJ. Simian virus 40-transformed adherent cells from human long-term marrow cultures: cloned cell lines produce cells with stromal and hematopoietic characteristics. *Blood.* 70:464-474, 1987.
48. Carlson SS, **Wight TN**. Nerve terminal anchorage protein 1(TAP-1) is a chondroitin sulfate proteoglycan: biochemical and electron microscopic characterization. *J Cell Biol.* 105:3075-3086, 1987.
49. **Wight TN**, Lark MW, Kinsella MG. Blood vessel proteoglycans. In: *The Biology of Proteoglycans.* Wight TN, Mecham RP, eds, Academic Press, NY, pp. 267-300, 1987.
50. **Wight TN**. Extracellular matrix changes in atherosclerosis. In: *Les Maladies de la Paroi Arterielle.* Camilleri JP, Berry CL, Fiessinger JN, Bariety J, eds, Flammarion, Paris, pp. 163-173, 1987. Translated as: Extracellular matrix changes in atherosclerosis. In: *Diseases of the Arterial Wall.* Springer-Verlag, Berlin Heidelberg, pp. 185-195, 1989.
51. Kinsella MG, **Wight TN**. Structural characterization of heparan sulfate proteoglycan subclasses isolated from bovine aortic endothelial cell cultures. *Biochemistry.* 27:2136-2144, 1988.
52. Sandell LJ, Sawhney RS, Yeo TK, Poole AR, Rosenberg LC, Kresse H, **Wight TN**. Cell-free translation of mRNA encoding an arterial smooth muscle proteoglycan core protein. *Eur J Cell Biol.* 46:253-258, 1988.
53. Lark MW, Yeo TK, Mar H, Lara S, Hellström I, Hellström KE, **Wight TN**. Arterial chondroitin sulfate proteoglycan: localization with a monoclonal antibody. *J Histochem Cytochem.* 36:1211-1221, 1988.

54. Mar H, **Wight TN**. Colloidal gold immunostaining on deplasticized ultra-thin sections. *J Histochem Cytochem.* 36:1387-1395, 1988.
55. Kinsella MG, **Wight TN**. Isolation and characterization of dermatan sulfate proteoglycans synthesized by cultured bovine aortic endothelial cells. *J Biol Chem.* 263:19222-19231, 1988.
56. Snow AD, Mar H, Nochlin D, Kimata K, Kato M, Suzuki S, Hassell J, **Wight TN**. The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. *Am J Pathol.* 133:456-463, 1988. *PMCID: PMC1880818*
57. Mar H, **Wight TN**. Correlative light and electron microscopic immunocytochemistry in reembedded resin sections with colloidal gold. In: *Colloidal Gold: Principles, Methods, & Applications*, vol II. Hayat MA, ed, Academic Press, Orlando, FL, pp. 357- 378, 1989.
58. Wechezak AR, **Wight TN**, Viggers RF, Sauvage LR. Endothelial adherence under shear stress is dependent upon microfilament reorganization. *J Cell Physiol.* 139:136-146, 1989.
59. **Wight TN**, Potter-Perigo S, Aulinskas T. Proteoglycans and vascular cell proliferation. *Am Rev Respir Dis.* 140:1132-1135, 1989. Review
60. Snow AD, Lara S, Nochlin D, **Wight TN**. Cationic dyes reveal proteoglycans structurally integrated within the characteristic lesions of Alzheimer's disease. *Acta Neuropathol (Berl).* 78:113-123, 1989.
61. Swedberg SH, Brown BG, Sigley R, **Wight TN**, Gordon D, Nichols SC. Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment. *Circulation.* 80:1726-1736, 1989.
62. Snow AD, Mar H, Nochlin D, **Wight TN**. Congo red staining on 1 micron de-plasticized sections for detection of lesions in Alzheimer's disease and related disorders. *Prog Clin Biol Res.* 317:383-91, 1989.
63. **Wight TN**. The cell biology of arterial proteoglycans. *Arteriosclerosis.* 9:1-20, 1989. Review
64. Snow AD, **Wight TN**. Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. *Neurobiol Aging.* 10:481-497, 1989. Review
65. Juul S, Ledbetter D, **Wight TN**, Woodrum D. New insights into idiopathic infantile arterial calcinosis. Three patient reports. *Am J Dis Child.* 144:229-233, 1990.
66. Snow AD, Bolender RP, **Wight TN**, Clowes AW. Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells. *Am J Pathol.* 137:313-330, 1990. *PMCID: PMC1877596*
67. Kinsella MG, **Wight TN**. Formation of high molecular weight of dermatan sulfate proteoglycan in bovine aortic endothelial cell cultures: evidence for transglutaminase-catalyzed cross-linking to fibronectin. *J Biol Chem.* 265:17891-17898, 1990.
68. Snow AD, **Wight TN**, Nochlin D, Koike Y, Kimata K, DeArmond SJ, Prusiner SB. Immunolocation of heparan sulfate proteoglycans to the prion protein amyloid plaques of Gerstmann-Straussler syndrome, Creutzfeldt-Jakob disease and scrapie. *Lab Invest.* 63:601-611, 1990.

69. Snow AD, Mar H, Nochlin D, Sekiguchi RT, Kimata K, Koike Y, **Wight TN**. Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome. *Am J Pathol.* 137:1253-1270, 1990. *PMCID: PMC1877656*
70. Levy BJ, **Wight TN**. Structural changes in the aging submucosa: new morphologic criteria for evaluation of the unstable human bladder. *J Urol.* 144:1044-1055, 1990.
71. Schönherr E, Järveläinen HT, Sandell LJ, **Wight TN**. Effects of platelet-derived growth factor and transforming growth factor- β 1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells. *J Biol Chem.* 266:17640-17647, 1991.
72. Järveläinen HT, Kinsella MG, **Wight TN**, Sandell LJ. Differential expression of small chondroitin/dermatan sulfate proteoglycans PG-I/biglycan and PG-II/decorin, by vascular smooth muscle and endothelial cells in culture. *J Biol Chem.* 266:23274-23281, 1991.
73. Snow AD, Bramson R, Mar H, **Wight TN**, Kisilevsky R. A temporal and ultrastructural relationship between heparan sulfate proteoglycans and AA amyloid in experimental amyloidosis. *J Histochem Cytochem.* 39:1321-1330, 1991.
74. Juul SE, **Wight TN**, Hascall VC. Proteoglycans. In: *The Lung: Scientific Foundations, vol I*. Crystal RC, West JB, eds, Raven Press, NY, pp. 413-420, 1991.
75. **Wight TN**. Dynamic interactions of proteoglycans. In: *Atherosclerosis: Cellular and Molecular Interactions in the Artery Wall*. Gotlieb AI, Langille BL, Fedoroff S, eds, Plenum Press, pp. 115-125, 1991.
76. **Wight TN**. Proteoglycans. In: *Encyclopedia of Human Biology, vol 6*. Dulbecco R, ed, Academic Press, NY, 1991.
77. **Wight TN**, Heinegard DK, Hascall VC. Proteoglycans: structure and function. In: *Cell Biology of Extracellular Matrix*. Hay ED, ed, Plenum Press, pp. 45-78, 1991.
78. Hascall VC, Heinegard DK, **Wight TN**. Proteoglycans: metabolism and pathology. In: *Cell Biology of Extracellular Matrix*. Hay ED, ed, Plenum Press, pp. 149-175, 1991.
79. Snow AD, Mar H, Nochlin D, Kresse H, **Wight TN**. Peripheral distribution of dermatan sulfate proteoglycans (decorin) in amyloid-containing plaques and their presence in neurofibrillary tangles of Alzheimer's disease. *J Histochem Cytochem.* 40:105-113, 1992.
80. Yeo TK, MacFarlane S, **Wight TN**. Characterization of a chondroitin sulfate proteoglycan synthesized by monkey arterial smooth muscle cells *in vitro*. *Connect Tiss Res.* 27:265-277, 1992.
81. Potter-Perigo S, Braun KR, Schönherr E, **Wight TN**. Altered proteoglycan synthesis via the false acceptor pathway can be dissociated from β -D-xyloside inhibition of proliferation. *Arch Biochem Biophys.* 297:101-109, 1992.
82. Qwarnström, EE, Kinsella MG, MacFarlane SA, Page RC, **Wight TN**. Modulation of proteoglycan metabolism by human fibroblasts maintained in an endogenous three-dimensional matrix. *Eur J Cell Biol.* 57:101-108, 1992.
83. Yeo TK, Yeo KT, **Wight TN**. Differential transport kinetics of chondroitin sulfate and dermatan sulfate proteoglycan by monkey aorta smooth muscle cells. *Arch Biochem Biophys.* 294:9-16, 1992.

84. Fukuchi K, Deeb SS, Kamino K, Ogburn CE, Snow AD, Sekiguchi RT, **Wight TN**, Piussan H, Martin GM. Increased expression of β -amyloid protein precursor and microtubule-associated protein τ during the differentiation of murine embryonal carcinoma cells. *J Neurochem.* 58:1863-1873, 1992.
85. Järveläinen HT, Iruela-Arispe ML, Kinsella MG, Sandell LJ, Sage EH, **Wight TN**. Expression of decorin by sprouting bovine aortic endothelial cells exhibiting angiogenesis *in vitro*. *Exp Cell Res.* 203:395-401, 1992.
86. **Wight TN**, Kinsella MG, Qwarnström EE. The role of proteoglycans in cell adhesion, migration and proliferation. *Curr Opin Cell Biol.* 4:793-801, 1992. Review
87. Juul SE, Kinsella MG, **Wight TN**, Hodson WA. Alterations in nonhuman primate (*M. nemestrina*) lung proteoglycans during normal development and acute hyaline membrane disease. *Am J Resp Cell Mol Biol.* 8:299-310, 1993.
88. Schönherr E, Järveläinen HT, Kinsella MG, Sandell LJ, **Wight TN**. Platelet-derived growth factor and transforming growth factor- β_1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells. *Arterioscler Thromb.* 13:1026-1036, 1993.
89. Potter-Perigo S, Prather P, Baker C, Altman LC, **Wight TN**. Partial characterization of proteoglycans synthesized by human gingival epithelial cells in culture. *J Periodontal Res.* 28:81-91, 1993.
90. Tillinghast EK, Townley MA, **Wight TN**, Uhlenbruck G, Janssen E. The adhesive glycoprotein of the orb web of *Argiope aurantia* (Araneae, Araneidae). In: *Biomolecular Materials*. Viney C, Case ST, Waite JH, eds, Materials Research Society Symposium Proceedings, pp. 292:9-23, 1993.
91. Klebanoff SJ, Kinsella MG, **Wight TN**. Degradation of endothelial cell matrix heparan sulfate proteoglycan by elastase and the myeloperoxidase-H₂O₂ chloride system. *Am J Pathol.* 143:907-917, 1993. *PMCID: PMC1887211*
92. Iwata M, **Wight TN**, Carlson SS. A brain extracellular matrix proteoglycan forms aggregates with hyaluronan. *J Biol Chem.* 268:15061-15069, 1993.
93. Qwarnström EE, Järveläinen HT, Kinsella MG, Ostberg CO, Sandell LJ, Page RC, **Wight TN**. Interleukin-1 β regulation of fibroblast proteoglycan synthesis involves a decrease in versican steady-state mRNA levels. *Biochem J.* 294:613-620, 1993. *PMCID: PMC1134499*
94. Yao LY, Moody C, Schönherr E, **Wight TN**, Sandell LJ. Identification of the proteoglycan versican in aorta and smooth muscle cells by DNA sequence analysis, *in situ* hybridization and immunohistochemistry. *Matrix Biol.* 14:213-225, 1994.
95. Nikkari ST, Järveläinen HT, **Wight TN**, Ferguson M, Clowes AW. Smooth muscle cell expression of extracellular matrix genes after arterial injury. *Am J Pathol.* 144:1348-1356, 1994. *PMCID: PMC1887477*
96. Riessen R, Isner JM, Blessing E, Loushin C, Nikol S, **Wight TN**. Regional differences in the distribution of proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic human coronary arteries. *Am J Pathol.* 144:962-974, 1994. *PMCID: PMC1887362*

97. Sekiguchi RT, Potter-Perigo S, Braun K, Miller J, Ngo C, Fukuchi K, **Wight TN**, Kimata K, Snow AD. Characterization of proteoglycans synthesized by murine embryonal carcinoma cells (P19) reveals increased expression of perlecan (heparan sulfate proteoglycan) during neuronal differentiation. *J Neurosci Res.* 38:670-686, 1994.
98. Savani RC, Wang C, Yang B, Zhang S, Kinsella MG, **Wight TN**, Stern R, Nance DM, Turley EA. Migration of bovine aortic smooth muscle cells after wounding injury. The role of hyaluronan and RHAMM. *J Clin Invest.* 95:1158-1168, 1995. *PMCID: PMC441453*
99. Snow AD, Kinsella MG, Parks E, Sekiguchi RT, Miller JD, Kimata K, **Wight TN**. Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease. *Arch Biochem Biophys.* 320:84-95, 1995.
100. Ostberg CO, Zhu P, **Wight TN**, Qwarnstrom E. Fibronectin attachment is permissive for IL-1 mediated gene regulation. *FEBS Lett.* 367:93-97, 1995.
101. **Wight TN**. The extracellular matrix and atherosclerosis. *Curr Opin Lipidol.* 6:326-334, 1995.
102. Levy BJ, **Wight TN**. The role of proteoglycans in bladder structure and function. *Adv Exp Med Biol.* 385:191-205, 1995. Review
103. Vernon RB, Lara SL, Drake CJ, Iruela-Arispe ML, Angello JC, Little CD, **Wight TN**, Sage EH. Organized type I collagen influences endothelial patterns during "spontaneous angiogenesis in vitro": planar cultures as models of vascular development. *In Vitro Cell Dev Biol Anim.* 31:120-31, 1995.
104. Lemire JM, Potter-Perigo S, Hall KL, **Wight TN**, Schwartz SM. Distinct rat aortic smooth muscle cells differ in versican/PG-M expression. *Arterioscler Thromb Vasc Biol.* 16:821-829, 1996.
105. Riessen R, **Wight TN**, Pastore C, Henley C, Isner JM. Distribution of hyaluronan during extracellular remodeling in human restenotic arteries and balloon-injured rat carotid arteries. *Circulation.* 93:1141-1147, 1996.
106. Carlson SS, Iwata M, **Wight TN**. A chondroitin sulfate/keratan sulfate proteoglycan, PG-1000 forms complexes which are concentrated in the reticular laminae of electric organ basement membranes. *Matrix Biol.* 15:281-292, 1996.
107. Potter-Perigo S, **Wight TN**. Heparin causes the accumulation of heparan sulfate in cultures of arterial smooth muscle cells. *Arch Biochem Biophys.* 336:19-26, 1996.
108. Halpert I, Sires UI, Roby JD, Potter-Perigo S, **Wight TN**, Shapiro SD, Welgus HG, Wickline SA, Parks WC. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. *Proc Nat Acad Sci USA.* 93:9748-9753, 1996. *PMCID: PMC38500*
109. **Wight TN**. The vascular extracellular matrix. In: *Atherosclerosis and Coronary Artery Disease*. Fuster V, Ross R, Topol E, eds, Lippincott-Raven Publishers, pp. 421-440, 1996.
110. **Wight TN**. Arterial wall. In: *Extracellular Matrix. Vol. 1. Tissue Function*. Comper W.D., ed. Amsterdam: Harwood Academic Publishers GmbH, pp. 175-202, 1996.

111. Kinsella MG, Tsoi CK, Järveläinen HT, **Wight TN**. Selective expression and processing of biglycan during migration of bovine aortic endothelial cells: The role of endogenous basic fibroblast growth factor. *J Biol Chem.* 272:318-325, 1997.
112. Schönherr E, Kinsella MG, **Wight TN**. Genistein selectively inhibits platelet-derived growth factor-stimulated versican biosynthesis in monkey arterial smooth muscle cells. *Arch Biochem Biophys.* 339:353-361, 1997.
113. **Wight TN**, Lara S, Riessen R, Le Baron R, Isner J. Selective deposits of versican in the extracellular matrix of restenotic lesions from human peripheral arteries. *Am J Pathol.* 151:963-973, 1997. *PMCID: PMC1858059*
114. Gutierrez P, O'Brien KD, Ferguson M, Nikkari ST, Alpers CE, **Wight TN**. Differences in the distribution of versican, decorin, and biglycan in atherosclerotic human coronary arteries. *Cardiovasc Pathol.* 6:271-278, 1997.
115. Miller JD, Cummings J, Maresh GA, Walker DG, Castillo GM, Ngo C, Kimata K, Kinsella MG, **Wight TN**, Snow AD. Localization of perlecan (or a perlecan-related macromolecule) to isolated microglia in vitro and to microglia/macrophages following infusion of beta-amyloid protein into rodent hippocampus. *Glia.* 21:228-243, 1997.
116. Castillo GM, Ngo C, Cummings J, **Wight T**, Snow AD. Perlecan binds to the β -amyloid proteins (A β) of Alzheimer's disease, accelerates A β fibril formation and maintains A β fibril stability. *J Neurochem.* 69:2452-2465, 1997.
117. Roberts CR, **Wight TN**, Hascall VC. Proteoglycans. In: *The Lung: Scientific Foundations*, 2nd edition. Crystal R, West JB, eds, Lippincott Raven Publishers, pp. 757-767, 1997.
118. Jabbour AJ, Altman LC, Baker C, **Wight TN**, Luchtel D. Ozone alters the distribution of β_1 integrins in cultured primate bronchial epithelial cells. *Am J Respir Cell Mol Biol.* 19:357-365, 1998.
119. Potter-Perigo S, Kaplan ED, Luchtel DL, Baker C, Altman LC, **Wight TN**. Ozone alters the expression of tenascin-C in cultured primate nasal epithelial cells. *Am J Respir Cell Mol Biol.* 18:471-478, 1998.
120. Evanko SP, Raines EW, Ross R, Gold LI, **Wight TN**. Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor- β . *Am J Pathol.* 152:533-546, 1998. *PMCID: PMC1857967*
121. Chang MY, Olin KL, Tsoi C, **Wight TN**, Chait A. Human monocyte-derived macrophages secrete two forms of proteoglycan-macrophage colony-stimulating factor that differ in their ability to bind low density lipoproteins. *J Biol Chem.* 273:15985-15992, 1998.
122. Koyama N, Kinsella MG, **Wight TN**, Hedin U, Clowes AW. Heparan sulfate proteoglycans mediate a potent inhibitory signal for migration of vascular smooth muscle cells. *Circ Res.* 83:305-313, 1998.
123. Borén J, Olin K, Lee I, Chait A, **Wight TN**, Innerarity TL. Identification of the principal proteoglycan-binding site in LDL: a single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. *J Clin Invest.* 101:2658-2664, 1998. *PMCID: PMC508856*

124. O'Brien KD, Olin KL, Alpers CE, Chiu W, Ferguson M, Hudkins K, **Wight TN**, Chait A. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. *Circulation*. 98:519-527, 1998.
125. Nikol S, Huehns TY, Weir L, **Wight TN**, Höfling B. Restenosis in human vein bypass grafts. *Atherosclerosis*. 139:31-39, 1998.
126. Chait A, Chang Y, Olin K, O'Brien K, **Wight TN**. Interaction of oxidized LDL with arterial proteoglycans. In: *Atherosclerosis XI*. Jacotot B, Mathe D, Fukhart JC, eds, Elsevier, pp. 79-82, 1998.
127. Evanko SP, Angello JC, **Wight TN**. Formation of hyaluronan- and versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol*. 19:1004-1013, 1999.
128. Lemire JM, Braun KR, Maurel P, Kaplan ED, Schwartz SM, **Wight TN**. Versican/PG-M isoforms in vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol*. 19:1630-1639, 1999.
129. Castillo GM, Lukito W, **Wight TN**, Snow AD. The sulfate moieties of glycosaminoglycans are critical for the enhancement of β -amyloid protein fibril formation. *J Neurochem*. 72:1681-1687, 1999.
130. Evanko SP, **Wight TN**. Intracellular localization of hyaluronan in proliferating cells. *J Histochem Cytochem*. 47:1331-1341, 1999.
131. Andrikopoulos S, Verchere CB, Teague JC, Howell WM, Fujimoto WY, **Wight TN**, Kahn SE. Two novel immortal pancreatic β -cell lines expressing and secreting human islet amyloid polypeptide do not spontaneously develop islet amyloid. *Diabetes*. 48:1962-1970, 1999.
132. Olin KL, Potter-Perigo S, Barrett PH, **Wight TN**, Chait A. Lipoprotein lipase enhances the binding of native and oxidized low density lipoproteins to versican and biglycan synthesized by cultured arterial smooth muscle cells. *J Biol Chem*. 274:34629-34636, 1999.
133. **Wight TN**. Hyaluronan in atherosclerosis and restenosis. Website Article, 1999. <http://www.glycoforum.gr.jp/science/hyaluronan/HA09/HA09E.html>
134. **Wight TN**. Biosynthesis of proteoglycans. In: *Comprehensive Natural Product Chemistry*, Vol III. Barton D, Nakanishi K, eds, Elsevier, pp. 161-178, 1999.
135. Chang MY, Potter-Perigo S, Tsoi C, Chait A, **Wight TN**. Oxidized low density lipoproteins regulate synthesis of monkey aortic smooth muscle cell proteoglycans that have enhanced native low density lipoprotein binding properties. *J Biol Chem*. 275:4766-4773, 2000.
136. Fischer JW, Kinsella MG, Clowes MM, Lara S, Clowes AW, **Wight TN**. Local expression of bovine decorin by cell-mediated gene transfer reduces neointimal formation after balloon injury in rats. *Circ Res*. 86:676-683, 2000.
137. Kaji T, Yamada A, Miyajima S, Yamamoto C, Fujiwara Y, **Wight TN**, Kinsella MG. Cell density-dependent regulation of proteoglycan synthesis by transforming growth factor- β_1 in cultured vascular endothelial cells. *J Biol Chem*. 275:1463-1470, 2000.

138. Kinsella MG, Fischer JW, Mason DP, **Wight TN**. Retrovirally mediated expression of decorin by macrovascular endothelial cells: effects on cellular migration and fibronectin fibrillogenesis *in vitro*. *J Biol Chem*. 275:13924-13932, 2000.
139. Sindelar BJ, Evanko SP, Alonzo T, Herring SW, **Wight T**. Effects of intraoral splint wear on proteoglycans in the temporomandibular joint disc. *Arch Biochem Biophys*. 379:64-70, 2000.
140. Kaneko E, Skinner MP, Raines EW, Yuan C, Rosenfeld ME, **Wight TN**, Ross, R. Detection of dissection and remodeling of atherosclerotic lesions in rabbits after balloon angioplasty by magnetic-resonance imaging. *Coron Artery Dis*. 11:599-606, 2000.
141. **Wight TN**. Proteoglycans and hyaluronan in vascular disease. In: *Carbohydrates in Chemistry and Biology*. Ernst B, Hart GW, Sinay P, eds, Wiley-VCH, pp. 743-755, 2000.
142. Chait A, **Wight TN**. Interaction of native and modified low-density lipoproteins with extracellular matrix. *Curr Opin Lipidol*. 11:457-463, 2000. Review
143. Olin KL, Potter-Perigo S, Barrett PH, **Wight TN**, Chait, A. Biglycan, a vascular proteoglycan, binds differently to HDL₂ and HDL₃: role of apoE. *Arterioscler Thromb Vasc Biol*. 21:129-135, 2001.
144. Chang MY, Potter-Perigo S, **Wight TN**, Chait A. Oxidized LDL bind to nonproteoglycan components of smooth muscle extracellular matrices. *J Lipid Res*. 42:824-833, 2001.
145. Lee RT, Yamamoto C, Feng Y, Potter-Perigo S, Briggs WH, Landschulz KT, Turi TG, Thompson JF, Libby P, **Wight TN**. Mechanical strain induces specific changes in the synthesis and organization of proteoglycans by vascular smooth muscle cells. *J Biol Chem*. 276:13847-13851, 2001.
146. Fischer JW, Kinsella MG, Levkau B, Clowes AW, **Wight TN**. Retroviral overexpression of decorin differentially affects the response of arterial smooth muscle cells to growth factors. *Arterioscler Thromb Vasc Biol*. 21:777-784, 2001.
147. Sandy JD, Westling J, Kenagy RD, Iruela-Arispe ML, Verscharen C, Rodriguez-Mazaneque JC, Zimmerman DR, Lemire JM, Fischer JW, **Wight TN**, Clowes AW. Versican VI proteolysis in human aorta *in vivo* occurs at the Glu⁴⁴¹-Ala⁴⁴² bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4. *J Biol Chem*. 276:13372-13378, 2001.
148. Lundmark K, Tran PK, Kinsella MG, Clowes AW, **Wight TN**, Hedin U. Perlecan inhibits smooth muscle cell adhesion to fibronectin: role of heparan sulfate. *J Cell Physiol*. 188:67-74, 2001.
149. Evanko SP, Johnson PY, Braun KR, Underhill CB, Dudhia J, **Wight TN**. Platelet-derived growth factor stimulates the formation of versican-hyaluronan aggregates and pericellular matrix expansion in arterial smooth muscle cells. *Arch Biochem Biophys*. 394:29-38, 2001.
150. Fischer JW, Kinsella MG, Hasenstab D, Clowes AW, **Wight TN**. Cell-mediated transfer of proteoglycan genes. *Methods Mol Biol*. 171:261-269, 2001.
151. Lara SL, Evanko SP, **Wight TN**. Morphological evaluation of proteoglycans in cells and tissues. *Methods Mol Biol*. 171:271-290, 2001. Review
152. Evanko S, **Wight TN**. Intracellular hyaluronan. Website article, 2001. <http://www.glycoforum.gr.jp/science/hyaluronan/HA20/HA20E.html>

153. Lemire JM, Merrilees MJ, Braun KR, **Wight TN**. Overexpression of the V3 variant of versican alters arterial smooth muscle cell adhesion migration, and proliferation in vitro. *J Cell Physiol.* 190:38-45, 2002.
154. Little PJ, Tannock L, Olin KL, Chait A, **Wight TN**. Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor- β 1 exhibit increased binding to LDLs. *Arterioscler Thromb Vasc Biol.* 22:55-60, 2002.
155. Tannock LR, Olin KL, Barrett PH, **Wight TN**, Chait A. Triglyceride-rich lipoproteins from subjects with type 2 diabetes do not demonstrate increased binding to biglycan, a vascular proteoglycan. *J Clin Endocrinol Metab.* 87:35-40, 2002.
156. Tannock LR, Little PJ, **Wight TN**, Chait A. Arterial smooth muscle cell proteoglycans synthesized in the presence of glucosamine demonstrate reduced binding to LDL. *J Lipid Res.* 43:149-157, 2002.
157. Merrilees MJ, Lemire JM, Fischer JW, Kinsella MG, Braun KR, Clowes AW, **Wight TN**. Retrovirally mediated overexpression of versican V3 by arterial smooth muscle cells induces tropoelastin synthesis and elastic fiber formation in vitro and in neointima after vascular injury. *Circ Res.* 90:481-487, 2002.
158. Kenagy RD, Fischer JW, Davies MG, Berceli SA, Hawkins SM, **Wight TN**, Clowes AW. Increased plasmin and serine protease activity during flow-induced intimal atrophy in baboon PTFE grafts. *Arterioscler Thromb Vasc Biol.* 22:400-404, 2002.
159. Olin-Lewis K, Benton JL, Rutledge JC, Baskin DG, **Wight TN**, Chait A. Apolipoprotein E mediates the retention of high-density lipoproteins by mouse carotid arteries and cultured arterial smooth muscle cell extracellular matrices. *Circ Res.* 90:1333-1339, 2002.
160. Yan Q, Clark JI, **Wight TN**, Sage EH. Alterations in the lens capsule contribute to cataractogenesis in SPARC-null mice. *J Cell Sci.* 115:2747-2756, 2002.
161. Finn AV, Gold HK, Tang A, Weber DK, **Wight TN**, Clermont A, Virmani R, Kolodgie FD. A novel rat model of carotid artery stenting for the understanding of restenosis in metabolic diseases. *J Vasc Res.* 39:414-425, 2002.
162. Chung IM, Gold HK, Schwartz SM, Ikari Y, Reidy MA, **Wight TN**. Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. *J Am Coll Cardiol.* 40:2072-2081, 2002.
163. Olin-Lewis K, Krauss RM, La Belle M, Blanche PJ, Barrett PH, **Wight TN**, Chait A. ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan, biglycan. *J Lipid Res.* 43:1969-1977, 2002.
164. Kolodgie FD, Burke AP, Farb A, Weber DK, Kutys R, **Wight TN**, Virmani R. Differential accumulation of proteoglycans and hyaluronan in culprit lesions: insights into plaque erosion. *Arterioscler Thromb Vasc Biol.* 22:1642-1648, 2002.
165. Virmani R, Kolodgie FD, Burke AP, Farb A, **Wight TN**. Structural and cellular components of the vulnerable plaque: extracellular matrix. In: *Assessing and Modifying the Vulnerable Atherosclerotic Plaque*. Fuster V, ed, Futura Publishing Co., Inc., pp. 241-250, 2002.
166. Toole BP, **Wight TN**, Tammi MI. Hyaluronan-cell interactions in cancer and vascular disease. *J Biol Chem.* 277:4593-4596, 2002. Review

167. Järveläinen H, **Wight TN**. Vascular proteoglycans. In: *Proteoglycans in Lung Disease*. Garg HG, Roughley, PJ, Hales CA, eds, Marcel Dekker, p. 291-321, 2002.
168. **Wight TN**. Versican: a versatile extracellular matrix proteoglycan in cell biology. *Curr Opin Cell Biol.* 14:617-623, 2002. Review.
169. Evanko SP, **Wight TN**. The presence and processing of intracellular hyaluronan in proliferating cells. In: *Hyaluronan, Vol. 1: Chemical, Biochemical and Biological Aspects*. eds. Kennedy JF, Phillips GO, Williams PA, Hascall VC, Woodhead Publishing, pp. 451-456, 2002.
170. **Wight TN**, Evanko SP. Hyaluronan is a critical component in atherosclerosis and restenosis and in determining arterial smooth muscle cell phenotype. In: *Hyaluronan, Vol. 2: Biomedical, Medical and Clinical Aspects*. Kennedy JF, Phillips GO, Williams PA, Hascall VC, eds, Woodhead Publishing, pp. 173-176, 2002.
171. Frevort CW, Kinsella MG, Vathanaprida C, Goodman RB, Baskin DG, Proudfoot A, Wells TN, **Wight TN**, Martin TR. Binding of interleukin-8 to heparan sulfate and chondroitin sulfate in lung tissue. *Am J Respir Cell Mol Biol.* 28:464-472, 2003.
172. Bradshaw AD, Puolakkainen P, Dasgupta J, Davidson JM, **Wight TN**, Sage EH. SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength. *J Invest Dermatol.* 120:949-955, 2003.
173. Puolakkainen P, Bradshaw AD, Kyriakides TR, Reed M, Brekken R, **Wight T**, Bornstein P, Ratner B, Sage EH. Compromised production of extracellular matrix in mice lacking secreted protein, acidic and rich in cysteine (SPARC) leads to a reduced foreign body reaction to implanted biomaterials. *Am J Pathol.* 162:627-635, 2003.
174. Somerville RP, Longpre JM, Jungers KA, Engle JM, Ross M, Evanko S, **Wight TN**, Leduc R, Apte SS. Characterization of ADAMTS-9 and ADAMTS-20 as a distinct ADAMTS subfamily related to *Caenorhabditis elegans* GON-1. *J Biol Chem.* 278:9503-9513, 2003.
175. Potter-Perigo S, Hull RL, Tsoi C, Braun KR, Andrikopoulos S, Teague J, Verchere CB, Kahn SE, **Wight TN**. Proteoglycans synthesized and secreted by pancreatic islet β -cells bind amylin. *Arch Biochem Biophys.* 413:182-190, 2003.
176. O'Brien KD, Vuletic S, McDonald TO, Wolfbauer G, Lewis K, Tu AY, Marcovina S, **Wight TN**, Chait A, Albers JJ. Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis. *Circulation.* 108:270-274, 2003.
177. Kinsella MG, Tran PK, Weiser-Evans MC, Reidy M, Majack RA, **Wight TN**. Changes in perlecan expression during vascular injury: role in the inhibition of smooth muscle cell proliferation in the late lesion. *Arterioscler Thromb Vasc Biol.* 23:608-614, 2003.
178. Chang MY, Tsoi C, **Wight TN**, Chait A. Lysophosphatidylcholine regulates synthesis of biglycan and the proteoglycan form of macrophage colony stimulating factor. *Arterioscler Thromb Vasc Biol.* 23:809-815, 2003.
179. Wrenshall LE, Platt JL, Stevens ET, **Wight TN**, Miller JD. Propagation and control of T cell responses by heparan sulfate-bound IL-2. *J Immunol.* 170:5470-5474, 2003.
180. Meyers CD, Tannock LR, **Wight TN**, Chait A. Statin-exposed vascular smooth muscle cells secrete proteoglycans with decreased binding affinity for LDL. *J Lipid Res.* 44:2152-2160, 2003.

181. Andrikopoulos S, Hull RL, Verchere CB, Wang F, Wilbur SM, **Wight TN**, Marzban L, Kahn SE. Extended life span is associated with insulin resistance in a transgenic mouse model of insulinoma secreting human islet amyloid polypeptide. *Am J Physiol Endocrinol Metab.* 286:E418-424, 2004.
182. Järveläinen H, Vernon RB, Gooden MD, Francki A, Lara S, Johnson PY, Kinsella MG, Sage EH, **Wight TN**. Overexpression of decorin by rat arterial smooth muscle cells enhances contraction of type 1 collagen in vitro. *Arterioscler Thromb Vasc Biol.* 24:67-72, 2004.
183. Hinek A, Braun KR, Liu K, Wang Y, **Wight TN**. Retrovirally mediated overexpression of versican V3 reverses impaired elastogenesis and heightened proliferation exhibited by fibroblasts from Costello syndrome and Hurler disease patients. *Am J Pathol.* 164:119-132, 2004. *PMCID: PMC1602235*
184. Potter-Perigo S, Baker C, Tsoi C, Braun KR, Isenhath S, Altman GM, Altman LC, **Wight TN**. Regulation of proteoglycan synthesis by leukotriene d4 and epidermal growth factor in bronchial smooth muscle cells. *Am J Respir Cell Mol Biol.* 30:101-108, 2004.
185. Burke AP, Järveläinen H, Kolodgie FD, Goel A, **Wight TN**, Virmani R. Superficial pseudoaneurysms: clinicopathologic aspects and involvement of extracellular matrix proteoglycans. *Mod Pathol.* 17:482-488, 2004.
186. Tannock LR, Little PJ, Tsoi C, Barrett PH, **Wight TN**, Chait A. Thiazolidinediones reduce the LDL binding affinity of non-human primate vascular cell proteoglycans. *Diabetologia.* 47:837-843, 2004.
187. Wilkinson TS, Potter-Perigo S, Tsoi C, Altman LC, **Wight TN**. Pro- and anti-inflammatory factors cooperate to control hyaluronan synthesis in lung fibroblasts. *Am J Respir Cell Mol Biol.* 31:92-99, 2004.
188. Grande-Allen KJ, Calabro A, Gupta V, **Wight TN**, Hascall VC, Vesely I. Glycosaminoglycans and proteoglycans in normal mitral valve leaflets and chordae: associations with regions of tensile and compressive loading. *Glycobiology.* 14:621-633, 2004.
189. Kinsella MG, Bressler S, **Wight TN**. The regulated synthesis of versican, decorin, and biglycan: extracellular matrix proteoglycans that influence cellular phenotype. *Crit Rev Eukaryot Gene Expr.* 14:203-234, 2004. Review.
190. **Wight TN**. The vascular extracellular matrix. In: *Atherothrombosis and Coronary Artery Disease*. Fuster V, Topel EJ, Nabel EG, eds, Lippincott Williams & Wilkins, pp. 421-437, 2005.
191. Hascall VC, Majors AK, de la Motte CA, Evanko SP, Wang A, Drazba JA, Strong SA, **Wight TN**. Intracellular hyaluronan: a new frontier for inflammation? *Biochem Biophys Acta.* 1673:3-12, 2004. Review. (*This paper was one of the top 10 papers downloaded from this journal in 2005.)
192. **Wight TN**, Evanko S, Kinsella MG, Chang M, Han CY, Sakr S, Huang R, Merrilees M, Rosenfeld M, Chait A. The pro-inflammatory nature of the extracellular matrix. In: *Atherosclerosis XIII*. Matsuzawa Y, Kita T, Nagai R, Teramoto T, eds, Elsevier, pp. 404-406, 2004.

193. Chait A, Lewis K, Tannock L, O'Brien K, Retzlaff G, Kahn S, Knopp R, **Wight TN**. Nutrition and inflammation: role of dietary cholesterol. In: *Atherosclerosis XIII*. Matsuzawa Y, Kita T, Nagai R, Teramoto T, eds, Elsevier, pp. 313-316, 2004.
194. Lewis KE, Kirk EA, McDonald TO, Wang S, **Wight TN**, O'Brien KD, Chait A. Increase in serum amyloid A evoked by dietary cholesterol is associated with increased atherosclerosis in mice. *Circulation*. 110:540-545, 2004.
195. **Wight TN**, Merrilees MJ. Proteoglycans in atherosclerosis and restenosis: key roles for versican. *Circ Res*. 94:1158-1167, 2004. Review.
196. Kinsella MG, Irvin C, Reidy MA, **Wight TN**. Removal of heparan sulfate by heparinase treatment inhibits FGF-2-dependent smooth muscle cell proliferation in injured rat carotid arteries. *Atherosclerosis*. 175:51-57, 2004.
197. **Wight TN**, Evanko S, Kolodgie F, Farb A, Virmani R. Hyaluronan in atherosclerosis and restenosis. In: *Chemistry and Biology of Hyaluronan*. Garg HG, Hales CA, eds, Elsevier, pp. 307-321, 2004.
198. Nigro J, Ballinger ML, Dilley RL, Jennings GL, **Wight TN**, Little PJ. Fenofibrate modifies human vascular smooth muscle proteoglycans and reduces lipoprotein binding. *Diabetologia*. 47:2105-2113, 2004.
199. Farb A, Kolodgie FD, Hwang JY, Burke AP, Tefera K, Weber DK, **Wight TN**, Virmani R. Extracellular matrix changes in stented human coronary arteries. *Circulation*. 110:940-947, 2004.
200. Kolodgie FD, Burke AP, **Wight TN**, Virmani R. The accumulation of specific types of proteoglycans in eroded plaques: a role in coronary thrombosis in the absence of rupture. *Curr Opin Lipidol*. 15:575-582, 2004. Review.
201. O'Brien KD, Lewis K, Fischer JW, Johnson P, Hwang JY, Knopp EA, Kinsella MG, Barrett PH, Chait A, **Wight TN**. Smooth muscle cell biglycan overexpression results in increased lipoprotein retention on extracellular matrix: implications for the retention of lipoproteins in atherosclerosis. *Atherosclerosis*. 177:29-35, 2004.
202. Fischer JW, Steitz SA, Johnson PY, Burke A, Kolodgie F, Virmani R, Giachelli C, **Wight TN**. Decorin promotes aortic smooth muscle cell calcification and colocalizes to calcified regions of human atherosclerotic lesions. *Arterioscler Thromb Vasc Biol*. 24:2391-2396, 2004.
203. Evanko SP, Parks WT, **Wight TN**. Intracellular hyaluronan in arterial smooth muscle cells: association with microtubules, RHAMM, and the mitotic spindle. *J Histochem Cytochem*. 52:1525-1535, 2004.
204. Kaji T, Sakurai S, Yamamoto C, Fujiwara Y, Yamagishi S, Yamamoto H, Kinsella MG, **Wight TN**. Characterization of chondroitin/dermatan sulfate proteoglycans synthesized by bovine retinal pericytes in culture. *Biol Pharm Bull*. 27:1763-1768, 2004.
205. Puolakkainen PA, Bradshaw AD, Brekken RA, Reed MJ, Kyriakides T, Funk SE, Gooden MD, Vernon RB, **Wight TN**, Bornstein P, Sage EH. SPARC-thrombospondin-2-double-null mice exhibit enhanced cutaneous wound healing and increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges. *J Histochem Cytochem*. 53:571-581, 2005.
206. Kenagy RD, Fischer JW, Lara S, Sandy JD, Clowes AW, **Wight TN**. Accumulation and loss of extracellular matrix during shear stress-mediated intimal growth and regression in

- baboon vascular grafts. *J Histochem Cytochem.* 53:131-140, 2005. *PMCID: PMC1451245*
207. Vernon RB, Gooden MD, Lara SL, **Wight TN**. Microgrooved fibrillar collagen membranes as scaffolds for cell support and alignment. *Biomaterials.* 26:3131-3140, 2005.
208. Vernon RB, Gooden MD, Lara SL, **Wight TN**. Native fibrillar collagen membranes of micron-scale and submicron thicknesses for cell support and perfusion. *Biomaterials.* 26:1109-1117, 2005.
209. Serra M, Miquel L, Domenzain C, Docampo MJ, Fabra A, **Wight TN**, Bassols A. V3 versican isoform expression alters the phenotype of melanoma cells and their tumorigenic potential. *Int J Cancer.* 114:879-886, 2005.
210. O'Brien KD, McDonald TO, Kunjathoor V, Eng K, Knopp EA, Lewis K, Lopez R, Kirk EA, Chait A, **Wight TN**, deBeer FC, Le Boeuf RC. Serum amyloid A and lipoprotein retention in murine models of atherosclerosis. *Arterioscler Thromb Vasc Biol.* 25:785-790, 2005.
211. **Wight TN**. The ADAMTS proteases, extracellular matrix, and vascular disease: waking the sleeping giant(s)! *Arterioscler Thromb Vasc Biol.* 25:12-14, 2005. Review.
212. Klüppel M, **Wight TN**, Chan C, Hinek A, Wrana JL. Maintenance of chondroitin sulfation balance by chondroitin-4-sulfotransferase 1 is required for chondrocyte development and growth factor signaling during cartilage morphogenesis. *Development.* 132:3989-4003, 2005.
213. Wilkinson TS, Bressler SL, Evanko SP, Braun KR, **Wight TN**. Overexpression of hyaluronan synthases alters vascular smooth muscle cell phenotype and promotes monocyte adhesion. *J Cell Physiol.* 206:378-385, 2006.
214. L'Heureux N, Dusserre N, Konig G, Victor B, Keire P, **Wight TN**, Chronos NA, Kyles AE, Gregory CR, Hoyt G, Robbins RC, McAllister TN. Human tissue-engineered blood vessels for adult arterial revascularization. *Nat Med.* 12:361-365, 2006. *PMCID: PMC1513140*
215. Kinsella MG, **Wight TN**. Perlecan: an extracellular matrix heparan sulfate proteoglycan that regulates key events in vascular development. In: *Chemistry and Biology of Heparin and Heparan Sulfate.* Garg HG, Linhardt RJ, Hales CA, eds, Elsevier, pp. 607-635, 2005.
216. Otsuka G, Agah R, Frutkin AD, **Wight TN**, Dichek DA. Transforming growth factor beta 1 induces neointima formation through plasminogen activator inhibitor-1-dependent pathways. *Arterioscler Thromb Vasc Biol.* 26:737-743, 2006.
217. Chang MY, Han CY, **Wight TN**, Chait, A. Antioxidants inhibit the ability of lysophosphatidylcholine to regulate proteoglycan synthesis. *Arterioscler Thromb Vasc Biol.* 26:494-500, 2006.
218. Huang R, Merrilees MJ, Braun K, Beaumont B, Lemire J, Clowes AW, Hinek A, **Wight TN**. Inhibition of versican synthesis by antisense alters smooth muscle cell phenotype and induces elastic fiber formation *in vitro* and in neointima after vascular injury. *Circ Res.* 98:370-377, 2006.
219. Varga R, Eriksson M, Erdos MR, Olive M, Harten I, Kolodgie F, Capell BC, Cheng J, Faddah D, Perkins S, Avallone H, San H, Qu X, Ganesh S, Gordon LB, Virmani R, **Wight**

- TN, Nabel EG, Collins FS. Progressive vascular smooth muscle defects in a mouse model of Hutchinson-Gilford progeria syndrome. *Proc Nat Acad Sci USA*. 103:3250-3255, 2006. *PMCID: PMC1413943*
220. Järveläinen H, Puolakkainen P, Pakkanen S, Brown EL, Höök M, Iozzo RV, Sage EH, **Wight TN**. A role for decorin in cutaneous wound healing and angiogenesis. *Wound Repair Regen*. 14:443-452, 2006.
221. Kenagy RD, Plaas AH, **Wight TN**. Versican degradation and vascular disease. *Trends in Cardiovasc Med*. 16:209-215, 2006. Review.
222. Frevort C, **Wight TN**. Matrix proteoglycans. In: *Encyclopedia of Respiratory Medicine*. Laurent GJ, Shapiro SJ, eds, Elsevier, pp 184-188, 2006.
223. Miguel-Serra L, Serra M, Hernandez D, Domenzain C, Docampo MJ, Rabanal RM, de Torres I, **Wight TN**, Fabra A, Bassols A. V3 versican isoform expression has a dual role in human melanoma tumor growth and metastasis. *Lab Invest*. 86:889-901, 2006.
224. Kaji T, Yamamoto C, Oh-i M, Fujiwara Y, Yamazaki Y, Morita T, Plaas AH, **Wight TN**. The vascular endothelial growth factor VEGF165 induces perlecan synthesis via VEGF receptor-2 in cultured human brain microvascular endothelial cells. *Biochim Biophys Acta*. 1760:1465-1474, 2006.
225. Sullivan MM, Barker TH, Funk SE, Karchin A, Seo NS, Höök M, Sanders J, Starcher B, **Wight TN**, Puolakkainen P, Sage EH. Matricellular hevin regulates decorin production and collagen assembly. *J Biol Chem*. 281:27621-27632, 2006.
226. Kuznetsova SA, Issa P, Perruccio EM, Zeng B, Sipes JM, Ward Y, Seyfried NT, Fielder HL, Day AJ, **Wight TN**, Roberts DD. Versican-thrombospondin-1 binding in vitro and colocalization in microfibrils induced by inflammation on vascular smooth muscle cells. *J Cell Sci*. 119:4499-4509, 2006.
227. Tannock LR, Kirk EA, King VL, LeBoeuf R, **Wight TN**, Chait A. Glucosamine supplementation accelerates early but not late atherosclerosis in LDL receptor-deficient mice. *J Nutr*. 136:2856-2861, 2006.
228. Kramer G, Laurie P, Neumann T, Rolle MW, **Wight TN**. Genetically engineered for increased elastin production tissue engineered microvessels composed of smooth muscle cells. *J Undergrad Res Bioengineering (UW)*. 6: 76-80, 2006.
229. Johnson PY, Potter-Perigo S, Gooden MD, Vernon RB, **Wight TN**. Decorin synthesized by arterial smooth muscle cells is selectively retained in fibrin gels and modulates fibrin contraction. *J Cell Biochem*. 101:281-294, 2007.
230. Lemire JM, Chan CK, Bressler S, Miller J, LeBaron RG, **Wight TN**. Interleukin-1 β selectively decreases the synthesis of versican by arterial smooth muscle cells. *J Cell Biochem*. 101:753-766, 2007.
231. Gouëffic Y, Potter-Perigo S, Chan CK, Johnson Y, Braun K, Evanko S, **Wight TN**. Sirolimus blocks the accumulation of hyaluronan (HA) by arterial smooth muscle cells and reduces monocyte adhesion to the ECM. *Atherosclerosis*. 195:23-30, 2007. *PMCID: PMC2504412*
232. Chira EC, McMillen TS, Wang S, Haw A 3rd, O'Brien KD, **Wight TN**, Chait A. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist,

- reduces atherosclerosis in female low density lipoprotein receptor deficient mice. *Atherosclerosis*. 195:100-109, 2007. *PMCID: PMC2702263*
233. Kolodgie FD, Burke AP, Farb A, Fowler DR, Kutys R, **Wight TN**, Virmani R. Plaque erosion. In: *The Vulnerable Atherosclerotic Plaque: Strategies for Diagnosis and Management*. Virmani R, Narula J, Leon MB & Willerson JT, eds, Blackwell Publishing, pp. 60-76, 2007.
234. Nakashima Y, Fujii H, Sumiyoshi S, **Wight TN**, Sueishi K. Early human atherosclerosis: Accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. *Arterioscler Thromb Vasc Biol*. 27:1159-65, 2007.
235. Bollyky PL, Lord JD, Masewicz SA, Evanko SP, Buckner JH, **Wight TN**, Nepom GT. High molecular weight hyaluronan promotes the suppressive effects of CD4+CD25+ regulatory T-cells. *J Immunol*. 179:744-747, 2007.
236. Han CY, Subramanian S, Chan CK, Omer M, Chiba T, **Wight TN**, Chait A. Adipocyte-derived serum amyloid A3 and hyaluronan play a role in monocyte recruitment and adhesion. *Diabetes*. 56:2260-2273, 2007.
237. McDonald TO, Gerrity RG, Jen C, Chen HJ, Wark K, **Wight TN**, Chait A, O'Brien KD. Diabetes and arterial extracellular matrix changes in a porcine model of atherosclerosis. *J Histochem Cytochem*. 55(11):1149-57, 2007.
238. Evanko SP, Tammi, MI, Tammi, RH, **Wight, TN**. Hyaluronan-dependent pericellular matrix. *Adv Drug Deliv Rev*. 59:1351-65, 2007. Review. *PMCID: PMC2174428*
239. Hull R, Zraika S, Udayasankar J, Kisilevsky R, Szarek WA, **Wight TN**, Kahn SE. Inhibition of glycosaminoglycans synthesis and protein glycosylation with WAS-405 and Azaserine result in reduced islet amyloid formation *in vitro*. *Am J Physiol Cell Physiol*. 293:C1586-93, 2007. *PMCID: PMC2365901*
240. Allison DD, Vasco N., Braun KR, Wight TN, Grande-Allen KJ. The effect of endogenous overexpression of hyaluronan synthases on material, morphological, and biochemical properties of uncrosslinked collagen biomaterials. *Biomaterials*. 28:5509-17, 2007.
241. Nigro J, Potter-Perigo S, Ivey ME, de Dios ST, Evanko SP, **Wight TN**, Little PJ. The effect of PPAR ligands to modulate glucose metabolism alters the incorporation of metabolic precursors into proteoglycans synthesized by human vascular smooth muscle cells. *Arch Physiol Biochem*. 114:171-7, 2008.
242. Miller JD, Stevens ET, Smith DR, **Wight TN**, Wrenshall LE. Perlecan: a major IL-2-binding proteoglycan in murine spleen. *Immunol Cell Biol*. 86:192-9, 2008.
243. Lowry MH, McAllister BP, Jean JC, Brown LA, Hughey RP, Cruikshank WW, Amar S, Lucey EC, Braun K, Johnson P, **Wight TN**, Joyce-Brady M. Lung lining fluid glutathione attenuates IL-13 induced asthma. *Am J Respir Cell Mol Biol*. 38:509-16. 2008. *PMCID: PMC2335334*
244. Nakashima Y, **Wight TN**, Sueishi K. Early atherosclerosis in humans: Role of diffuse intimal thickening and extracellular matrix proteoglycans. *Cardiovasc Res*. 79:14-23. 2008. Review.
245. Allison DD, Vasco N, Braun KR, **Wight TN**, Grande-Allen KJ. Endogenous overexpression of hyaluronan synthases within dynamically cultured collagen gels: Implications for vascular and valvular disease. *Biomaterials*. 29:2969-76, 2008.

246. Merrilees MJ, Ching PS, Beaumont B, Hinek A, Wight TN, Black PN. Changes in elastin, elastin binding protein and versican in alveoli in chronic obstructive pulmonary disease. *Respir Res.* 9:41, 2008. *PMCID: PMC2397404*
247. **Wight TN.** Arterial remodeling in vascular disease: a key role for hyaluronan and versican. *Front Biosci.* 13:4933-4937, 2008. Review.
248. Tran-Lundmark K, Tran PK, Paulsson-Berne G, Fridén V, Soininen R, Tryggvason K, **Wight TN**, Kinsella MG, Borén J, Hedin U. Heparan sulfate in perlecan promotes mouse atherosclerosis. Roles in lipid permeability, lipid retention, and smooth muscle cell proliferation. *Circ Res.* 103:43-52, 2008. *PMCID: PMC2765377*
249. True LD, Norwood TH, Braun K, Evanko S, Chan C, LeBaron RC, **Wight TN.** The accumulation of versican in the nodules of benign prostatic hyperplasia. *The Prostate.* 69:149-58, 2009. *PMCID: PMC4092210*
250. Seidelmann SB, Kuo C, Pleskac N, Molina J, Sayers S, Li R, Zhou J, Johnson P, Braun K, Chan C, Teupser D, Breslow JL, **Wight TN**, Tall AR, Welch CL. *Athsq1* is an atherosclerosis modifier locus with dramatic effects on lesion area and prominent accumulation of versican. *Arterioscler Thromb Vasc Biol.* 28:2180-6, 2008. *PMCID: PMC2784896*
251. Hwang JY, Johnson PY, Braun KR, Hinek A, Fischer JW, O'Brien KD, Starcher B, Clowes AW, Merrilees MJ, **Wight TN.** Retrovirally-mediated overexpression of glycosaminoglycan-deficient biglycan in arterial smooth muscle cells induces tropoelastin synthesis and elastic fiber formation *in vitro* and in neointima after vascular injury. *Am J Pathol.* 173:1919-28, 2008. *PMCID: PMC2626402*
252. Sakr SW, Potter-Perigo S, Kinsella MG, Johnson PY, Braun KR, Gouëffic Y, Rosenfeld ME, **Wight TN.** Hyaluronan accumulation is elevated in cultures of LDL receptor-deficient cells is altered by manipulation of cell cholesterol content. *J Biol Chem.* 283:36195-204, 2008. *PMCID: PMC2606012*
253. Allison DD, Braun KR, **Wight TN**, Grande-Allen KJ. Differential effects of exogenous and endogenous hyaluronan on contraction and strength of collagen gels. *Acta Biomater.* 5:1019-26, 2009. *No Federal Support*
254. Bollyky PL, Falk BA, Wu RP, Buckner JH, **Wight TN**, Nepom GT. Intact extracellular matrix and the maintenance of immune tolerance: high molecular weight hyaluronan promotes persistence of induced CD4⁺CD25⁺ regulatory T cells. *J. Leukoc Biol.* 86(3):567-72, 2009. Review. *PMCID: PMC2735281*
255. Järveläinen H, Sainio A, Koulu M, **Wight TN**, Penttinen R. Extracellular matrix molecules: potential targets in pharmacotherapy. *Pharmacol Rev.* 61:198-223, 2009. Review. *PMCID: PMC2830117*
256. Evanko S, Potter-Perigo S, Johnson P, **Wight T.** Organization of hyaluronan and versican in the extracellular matrix of human fibroblasts treated with the viral mimetic, poly I:C. *J Histochem Cytochem.* 57:1041-60, 2009. *PMCID: PMC2762883*
257. Fleming JN, Shulman HM, Nash RA, Johnson PY, **Wight TN**, Gown A, Schwartz SM. Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis. *PLoS One.* 4:e6203, 2009. *PMCID: PMC2705674*

258. Potter-Perigo S, Johnson PY, Evanko SP, Chan CK, Braun KR, Wilkinson TS, Altman LC, **Wight TN**. Polyinosine-polycytidylic acid stimulates versican accumulation in the extracellular matrix promoting monocyte adhesion. *Am J Resp Cell Molec Biol.* 43:109-20, 2010. *PMCID: PMC2911565*
259. Bollyky PL, Falk BA, Long SA, Preisinger A, Braun KR, Wu RP, Evanko SP, Buckner JH, **Wight TN**, Nepom GT. CD44 costimulation promotes FoxP3+ regulatory T cell persistence and function via production of IL-2, IL-10, and TGF-beta. *J Immunol.* 183:2232-41, 2009. *PMCID: PMC3057032*
260. Keire PA, L'Heureux N, Vernon RB, Merrilees MJ, Starcher B, Okon E, Dusserre N, McAllister TN, **Wight TN**. Expression of versican isoform V3 in the absence of ascorbate improves elastogenesis in engineered vascular constructs. *Tissue Eng.* 16:501-512, 2010. *PMCID: PMC2813184*
261. Han CY, Kargi AY, Omer M, Chan CK, Wabitsch M, O'Brien KD, **Wight TN**, Chait A. Differential effect of saturated and unsaturated free fatty acids on the generation of monocyte adhesion and chemotactic factors by adipocytes: dissociation of adipocyte hypertrophy from inflammation. *Diabetes.* 59:386-96, 2010. *PMCID: PMC2809975*
262. Gill SE, **Wight TN**, Frevert CW. Proteoglycans: key regulators of pulmonary inflammation and the innate immune response to lung infection. *Anat Rec. (Hoboken)* 293:968-981, 2010. Review. *PMCID: PMC4121077*
263. Tanino Y, Coombe DR, Gill SE, Kett WC, Kajikawa O, Proudfoot AE, Wells TN, Parks WC, **Wight TN**, Martin TR, Frevert CW. Kinetics of chemokine-glycosaminoglycan interactions control neutrophil migration into the airspaces of the lungs. *J Immunol.* 184:2677-85, 2010. *PMCID: PMC4113427*
264. Chung I-M, Kim J, Pak Yk, Jang Y, Yang W-I, Han I, Park S-J, Park S-W, Huh, J, **Wight TN**, Ueno H. Blockade of TGF- β by catheter-based local intravascular gene delivery does not alter the in-stent neointimal response, but enhances inflammation in pig coronary arteries. *Int J Cardiol.* 145:468-75, 2010. *PMCID: PMC4100469*
265. Shukla S, Nair R, Rolle MW, Braun KR, Chan CK, Johnson PY, **Wight TN**, McDevitt TC. Synthesis and organization of hyaluronan and versican by embryonic stem cells undergoing embryoid body differentiation. *J Histochem Cytochem.* 58:345-58, 2010. *PMCID: PMC2842597*
266. Cardoso LEM, Little PJ, Ballinger ML, Chan CK, Braun KR, Potter-Perigo S, Bornfeldt KE, Kinsella MG, **Wight TN**. Platelet-derived growth factor differentially regulates the expression and post-translational modification of versican by arterial smooth muscle cells through distinct protein kinase C and extracellular signal-regulated kinase pathways. *J Biol Chem.* 285:6987-95, 2010. *PMCID: PMC2844148*
267. Bollyky PL, Evanko SP, Wu RP, Perigo S, Long SA, Kinsella B, Reijonen H, Guebtner K, Teng B, Chan CK, Braun KR, Gebe J, Nepom GT, **Wight TN**. TH1 cytokines promote hyaluronan production by antigen presenting cells and accumulation at the immune synapse. *Cell Mol Immunol.* 7:211-20, 2010. *PMCID: PMC3027489*
268. Getachew R, Ballinger ML, Burch ML, Reid JJ, Khachigian LM, **Wight TN**, Little PJ, Osman N. PDGF β receptor kinase activity and ERK1/2 mediate glycosaminoglycan elongation on biglycan and increases binding to LDL. *Endocrinol.* 151:4356-67, 2010.

269. Chan CK, Rolle MW, Potter-Perigo S, Braun KR, Van Biber BP, Laflamme MA, Murry CE, **Wight TN**. Differentiation of cardiomyocytes from human embryonic stem cells is accompanied by changes in the extracellular matrix production of versican and hyaluronan. *J Cell Biochem*. 111:585-96, 2010. *PMCID: PMC2946489*
270. Olive M, Harten I, Mitchell R, Beers J, Djabali K, Cao K, Erdos MR, Blair C, Funke B, Smoot L, Gerhard-Herman M, Machan JT, Kutys R, Virmani R, Collins FS, **Wight TN**, Nabel EG, Gordon LB. Cardiovascular pathology in Hutchinson-Gilford Progeria: Correlation with the vascular pathology of aging. *Arterioscler Thromb Vasc Biol*. 30:2301-9, 2010. *PMCID: PMC2965471*
271. **Wight TN**, Toole BP, Hascall VC. Hyaluronan and the aggregating proteoglycans. In: *The Extracellular Matrix: an Overview*. Mecham RP, ed. Berlin-Heidelberg: Springer-Verlag, pp. 147-195, 2011.
272. Angheloiu GO, Haka AS, Georgakoudi I, Arendt J, Müller MG, Scepanovic OR, Evanko SP, **Wight TN**, Mukherjee P, Waldeck DH, Dasari RR, Fitzmaurice M, Kramer JR, Feld MS. Detection of coronary atherosclerotic plaques with superficial proteoglycans and foam cells using real-time intrinsic fluorescence spectroscopy. *Atherosclerosis*. 215:96-102, 2011. *PMCID: PMC3049853*
273. Fu Y, Nagy J, Brown L, Shih S-C, Johnson PY, Chan CK, Dvorak H, **Wight TN**. Proteolytic cleavage of versican and involvement of ADAMTS-1 in VEGF-A/VPF-induced pathological angiogenesis. *J Histochem Cytochem*. 59:463-475, 2011. *PMCID: PMC3201172*
274. Kreutziger KL, Muskheli V, Johnson P, Braun K, **Wight TN**, Murry CE. Developing vasculature and stroma in engineered human myocardium. *Tissue Eng Part A*. 17:1219-28, 2011. *PMCID: PMC3079173*
275. Merrilees MJ, Beaumont BW, Braun KR, Thomas AC, Kang I, Hinek A, Passi A, **Wight TN**. Neointima formed by arterial smooth muscle cells expressing versican variant V3 is resistant to lipid and macrophage accumulation. *Arterioscler Thromb Vasc Biol*. 31:1309-16, 2011. *PMCID: PMC3123728*
276. Bollyky PL, Wu RP, Falk BA, Lord JD, Long SA, Preisinger A, Teng B, Holt GE, Standifer NE, Braun KR, Xie C, Samuels PL, Vernon RB, Gebe JA, **Wight TN**, Nepom GT. ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors. *Proc Natl Acad Sci U S A*. 108:7938-7943, 2011. *PMCID: PMC3093524*
277. Chiba T, Chang MY, Wang S, **Wight TN**, McMillen TS, Oram JF, Vaisar T, Heinecke JW, De Beer FC, De Beer MC, Chait A. Serum amyloid A facilitates the binding of high-density lipoprotein from mice injected with lipopolysaccharide to vascular proteoglycans. *Arterioscler Thromb Vasc Biol*. 31:1326-1332, 2011. *PMCID: PMC3129975*
278. **Wight TN**, Potter-Perigo S. The extracellular matrix: an active or passive player in fibrosis. *Am J Physiol Gastrointest Liver Physiol*. 301:G950-955, 2011. Review. *PMCID: PMC3233785*
279. Harten IA, Zahr RS, Lemire JM, Machan JT, Moses MA, Doiron RJ, Curatolo AS, Rothman FG, **Wight TN**, Toole BP, Gordon LB. Age-dependent loss of MMP-3 in Hutchinson-Gilford Progeria Syndrome. *J Gerontol A Biol Sci Med Sci*. 66:1201-7, 2011. *PMCID: PMC3193525*

280. Evanko SP, Potter-Perigo S, Bollyky PL, Nepom GT, **Wight TN**. Hyaluronan and versican in the control of human T lymphocyte adhesion and migration. *Matrix Biol.* 31:90-100, 2012. *PMCID: PMC3288568*
281. Kanter JE, Kramer F, Barnhart S, Averill MM, Vivekanandan-Giri A, Vickery T, Li LO, Becker L, Yuan W, Chait A, Braun KR, Potter-Perigo S, Sanda S, **Wight TN**, Pennathur S, Serhan CN, Heinecke JW, Coleman RA, Bornfeldt KE. Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis via acyl-CoA synthetase 1. *Proc Natl Acad Sci U S A.* 109:E715-24, 2012. *PMCID: PMC3311324*
282. **Wight TN**. The pathobiology of versican. In: *Extracellular Matrix: Pathobiology and Signaling*. Nikos Karamanos, Ed. Berlin: Walter De Gruyter GMBH & Co., KG, 2012, pp. 154-170.
283. Chang MY, Chan CK, Braun KR, Green PS, O'Brien KD, Chait A, Day AJ, **Wight TN**. Monocyte-to-macrophage differentiation: Synthesis and secretion of a complex extracellular matrix. *J Biol Chem.* 287:14122-14135, 2012. *PMCID: PMC3340194*
284. Tanino Y, Chang MY, Wang X, Gill SE, Skerrett S, McGuire JK, Sato S, Nikaido T, Kojima T, Munakata M, Mongovin S, Parks WC, Martin TR, **Wight TN**, Frevert CW. Syndecan-4 regulated early neutrophil migration and pulmonary inflammation in response to lipopolysaccharide. *Am J Respir Cell Mol Biol.* 47:196-202, 2012. *PMCID: PMC3423465*
285. Merrilees MJ, **Wight TN**. Targeting the matrix: potential benefits for versican therapeutics. *Current Comments*. 2012. <http://www.elsevierblogs.com/currentcomments/>
286. Bollyky PL, Bogdani M, Bollyky J, Hull R, **Wight TN**. The role of hyaluronan and the extracellular matrix in islet inflammation and immune regulation. *Curr Diab Rep.* 12:471-80, 2012. Review. *PMCID: PMC3432646*
287. Hull RL, Johnson PY, Braun KR, Day AJ, **Wight TN**. Hyaluronan and hyaluronan binding proteins are normal components of mouse pancreatic islets and are differentially expressed by islet endocrine cell types. *J Histochem Cytochem.* 60:749-60, 2012. *PMCID: PMC3524560*
288. Hull RL, Peters MJ, Potter-Perigo S, Chan CK, **Wight TN**, Kinsella MG. Overall sulfation of heparan sulfate from pancreatic islet β -TC3 cells increases maximal fibril formation but does not determine binding to the amyloidogenic peptide islet amyloid polypeptide. *J Biol Chem.* 287:37154-64, 2012. *PMCID: PMC3481315*
289. **Wight TN**. The biomatrix of the vascular system and the control of cell phenotype. In: *Hyaluronan: From Basic Science to Clinical Applications*, vol 5. Structure and Function of Biomatrix: Control of Cell Behavior and Gene Expression. Balazs, EA, Ed. Matrix Biology Institute, Edgewater, NJ, pp. 315-340, 2012.
290. Ayars AG, Altman LC, Potter-Perigo S, Radford K, **Wight TN**, Nair P. Sputum hyaluronan and versican in severe eosinophilic asthma. *Int Arch Allergy Immunol.* 161:65-73, 2013. *PMCID: PMC4059000*
291. Reed MJ, Damodarasamy M, Chan CK, Johnson MNR, **Wight TN**, Vernon RB. Cleavage of hyaluronan is impaired in aged dermal wounds. *Matrix Biol.* 32:45-51, 2013. *PMCID: PMC3570623*

292. Rutnam ZJ, **Wight TN**, Yang BB. miRNAs regulate expression and function of extracellular matrix molecules. *Matrix Biol.* 32:74-85, 2013. Review. *PMCID: PMC4106267*
293. Wilson CL, Gough PJ, Chang CA, Chan CK, Frey JM, Liu Y, Braun KR, Chin MT, **Wight TN**, Raines EW. Endothelial deletion of ADAM17 in mice results in defective remodeling of the semilunar valves and cardiac dysfunction in adults. *Mech Dev.* 130:272-89, 2013. *PMCID: PMC3622831*
294. Viola M, Bartolini B, Vigetti D, Karousou E, Moretto P, Deleonibus S, Sawamura T, **Wight TN**, Hascall VC, De Luca G, Passi A. Oxidized LDL affects hyaluronan synthesis in human aortic smooth muscle cells. *J Biol Chem.* 288:29595-29603, 2013. *PMCID: PMC3795257*
295. Obika M, Vernon RB, Gooden MD, Braun KR, Chan CK, **Wight TN**. ADAMTS-4 and biglycan are expressed at high levels and co-localize to podosomes during endothelial cell tubulogenesis in vitro. *J Histochem Cytochem.* 62:34-49, 2014. *PMCID: PMC3873805*
296. **Wight TN**, Kinsella MG, Evanko SP, Potter-Perigo S, Merrilees MJ. Versican and the regulation of cell phenotype in disease. *Biochim Biophys Acta (Gen Subjs).* 1840:2441-2451, 2014. Review. *PMCID: PMC4074575*
297. Chang MY, Tanino Y, Vidova V, Kinsella MG, Chan CK, Johnson PY, **Wight TN**, Frevert CW. A rapid increase in macrophage-derived versican and hyaluronan in infectious lung disease. *Matrix Biol.* 34:1-12, 2014. *PMCID: PMC4019684*
298. **Wight TN**, Kang I, Merrilees MJ. Versican and the control of inflammation. *Matrix Biol.* 35:152-61, 2014. Review. *PMCID: PMC4039577*
299. Ruppert SM, Hawn TR, Arrigoni A, **Wight TN**, Bollyky PL. Tissue integrity signals communicated by high-molecular weight hyaluronan and the resolution of inflammation. *Immunol Res.* 58:186-92, 2014. Review. *PMCID: PMC4106675*
300. Bogdani M, Johnson PY, Potter-Perigo S, Nagy N, Day AJ, Bollyky PL, **Wight TN**. Hyaluronan and hyaluronan binding proteins accumulate in both human type 1 diabetic islets and lymphoid tissues and associate with inflammatory cells in insulinitis. *Diabetes.* 63:2727-2743, 2014. *PMCID: PMC4113060*
301. Reeves SR, Kolstad T, Lien T-Y, Elliott M, Ziegler SF, **Wight TN**, Debley JS. Asthmatic airway epithelial cells differentially regulate fibroblast expression of extracellular matrix components. *J Allergy Clin Immunol.* 134:663-670, 2014. *PMCID: PMC4149938*
302. Kang I, Yoon DW, Braun KR, **Wight TN**. Expression of versican V3 by arterial smooth muscle cells alters TGF β -, EGF-, and NF κ B-dependent signaling pathways, creating a microenvironment that resists monocyte adhesion. *J Biol Chem.* 289:15393-15404, 2014. *PMCID: PMC4140896*
303. Merrilees MJ, Falk B, Zuo N, Dickinson M, May B, **Wight TN**. Use of versican variant V3 and versican antisense expression to engineer cultured human skin containing increased content of insoluble elastin. *J Tiss Eng Regen Med.* 11:295-305, 2017.
304. Harten IA, Olive M, **Wight TN**. Vascular disease in Hutchinson Gilford progeria syndrome and aging: Common phenotypes and potential mechanisms. In: *Handbook of the Biology of Aging, Eighth Edition*. Kaeberlein MR and Martin GM, eds. Amsterdam: Elsevier, pp. 433-457, 2016.

305. Damodarasamy M, Vernon RB, Chan CK, Plymate SR, **Wight TN**, Reed MJ. Hyaluronan in aged collagen matrix increases prostate epithelial cell proliferation. *In Vitro Cell Dev Biol (Animal)*. 51:50-58, 2015. *PMCID: PMC4571456*
306. Bogdani M, Korpos E, Simeonovic CJ, Parish CR, Sorokin L, **Wight TN**. Extracellular matrix components in the pathogenesis of type 1 diabetes. *Curr Diab Rep*. 14(12):552, 2014. Review. *PMCID: PMC4238291*
307. Bogdani M, Simeonovic CJ, Nagy N, Johnson PY, Chan CK, **Wight TN**. The detection of glycosaminoglycans in pancreatic islets and lymphoid tissues. In: Balagurunathan K., et al. (eds.), *Glycosaminoglycans: Chemistry and Biology*. *Methods Mol Biol*. 1229:413-30, 2015. *PMCID: PMC4234048*
308. Keire PA, Bressler SL, Lemire JM, Edris B, Rubin BP, Rahmani M, McManus BM, van de Rijn M, **Wight TN**. A role for versican in the development of leiomyosarcoma. *J Biol Chem*. 289:34089-103, 2014. *PMCID: PMC4256343*
309. Kikuchi S, Kenagy RD, Gao L, **Wight TN**, Sobel M, Clowes AW. Surgical marking pen dye inhibits saphenous vein cell proliferation and migration in saphenous vein graft tissue. *J Vasc Surg*. 63:1044-50, 2016. *PMCID: PMC4627895*
310. Evanko SP, Potter-Perigo S, Petty LJ, Workman GA, **Wight TN**. Hyaluronan controls the deposition of fibronectin and collagen and modulates TGF- β 1 induction of lung myofibroblasts. *Matrix Biol*. 42:74-92, 2015. *PMCID: PMC4524654*
311. Hull RL, Bogdani M, Nagy N, Johnson PY, **Wight TN**. Hyaluronan: A mediator of islet dysfunction and destruction in diabetes? *J Histochem Cytochem*. 8:592-603, 2015. Review. *PMCID: PMC4530396*
312. Järveläinen H, Sainio A, **Wight TN**. A pivotal role for decorin in angiogenesis. *Matrix Biol*. 43:15-26, 2015. Review. *PMCID: PMC4560244*
313. Nagy N, Kuipers HF, Frymoyer AR, Ishak HD, Bollyky JB, **Wight TN**, Bollyky PL. 4-Methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer. *Front Immunol*. 6:123, 2015. Review. *PMCID: PMC4369655*
314. Otsuka F, Kramer MC, Woudstra P, Yahagi K, Ladich E, Finn AV, de Winter RJ, Kolodgie FD, **Wight TN**, Davis HR, Joner M, Virmani R. Natural progression of atherosclerosis from pathologic intimal thickening to late fibroatheroma in human coronary arteries: A pathology study. *Atherosclerosis*. 241:772-82, 2015. *PMCID: PMC4510015*
315. Kang I, Barth JL, Sproul EP, Yoon DW, Workman GA, Braun KR, Argraves WS, **Wight TN**. Expression of V3 versican by rat arterial smooth muscle cells promotes differentiated and anti-inflammatory phenotypes. *J Biol Chem*. 290:21629-41, 2015. *PMCID: PMC4571886*
316. Merrilees MJ, Kang I, Hinek A, **Wight TN**. Regulating elastogenesis using proteoglycans. In: *Elastic Fiber Matrices: Biomimetic Approaches to Regeneration and Repair*. Ramamurthi A, Kothapalli C, eds. Boca Raton, FL: CRC Press/Taylor & Francis, pp. 255-284, 2016.
317. Nagy N, Kaber G, Johnson PY, Gebe JA, Preisinger A, Falk BA, Sunkari VG, Gooden MD, Vernon RB, Bogdani M, Kuipers HF, Day AJ, Campbell DJ, **Wight TN**, Bollyky

- PL. Inhibition of hyaluronan synthesis restores immune tolerance during autoimmune insulinitis. *J Clin Invest.* 25:3928-40, 2015. *PMCID: PMC4607113*
318. Hu JH, Wei H, Jaffe M, Airhart N, Du L, Angelov SN, Yan J, Allen JK, Kang I, **Wight TN**, Fox K, Smith A, Enstrom R, Dicheck DA. Postnatal deletion of the type II TGF-beta receptor in smooth muscle cells causes severe aortopathy in mice. *Arterioscler Thromb Vasc Biol.* 35:2647-56, 2015. *PMCID: PMC4743752*
319. Han CY, Tang C, Guevara ME, Wei H, Wietecha T, Shao B, Subramanian S, Omer M, Wang S, O'Brien KD, **Wight TN**, Vaisar T, de Beer MC, de Beer FC, Osborne WR, Elkon KB, Chait A. Serum amyloid A impairs the anti-inflammatory properties of HDL. *J Clin Invest.* 126:266-281, 2016. *PMCID: PMC4701569*
320. Keire PA, Bressler SL, Mulvihill ER, Starcher BC, Kang I, **Wight TN**. Inhibition of versican expression by siRNA facilitates tropoelastin synthesis and elastic fiber formation by human SK-LMS-1 leiomyosarcoma smooth muscle cells *in vitro* and *in vivo*. *Matrix Biol.* 50:67-81, 2016. *PMCID: PMC4808388*
321. Kuipers HF, Rieck M, Gurevich I, Butte MJ, Negrin RS, **Wight TN**, Steinman L, Bollyky PL. Hyaluronan synthesis is necessary for autoreactive T cell trafficking, activation, and Th1 polarization. *Proc Natl Acad Sci U S A.* 113:1339-44, 2016. *PMCID: PMC4747722*
322. Reeves SR, Kaber G, Sheih A, Cheng G, Aronica MA, Merrilees MJ, Debley JS, Frevert CW, Ziegler SF, **Wight TN**. Subepithelial accumulation of versican in a cockroach antigen-induced murine model of allergic asthma. *J Histochem Cytochem.* 64:364-390, 2016. *PMCID: PMC4888411*
323. Merrilees MJ, Zuo N, Evanko SP, Day AJ, **Wight TN**. G1 domain of versican regulates hyaluronan organization and the phenotype of cultured human dermal fibroblasts. *J Histochem Cytochem.* 64:353-363, 2016. *PMCID: PMC4888412*
324. Chang Y-T, Chan CK, Eriksson I, Johnson PY, Cao X, Andersson-Sjöland A, Westergren-Thorsson G, Rabinovitch M, Johansson S, Hedin U, Kjellén L, **Wight TN**, Tran-Lundmark K. Versican accumulates in vascular lesions in pulmonary arterial hypertension. *Pulm Circ.* 6:347-359, 2016. *PMCID: PMC5019088*
325. Kuipers HF, Nagy N, Ruppert SM, Sunkari VG, Marshall PL, Gebe JA, Ishak HD, Keswani SG, Bollyky J, Frymoyer AR, **Wight TN**, Steinman L, Bollyky PL. The pharmacokinetics and dosing of oral 4-methylumbelliferone for inhibition of hyaluronan synthesis in mice. *Clin Exp Immunol.* 185:372-81, 2016. *PMCID: PMC4991418*
326. Hundhausen C, Roth A, Whalen E, Chen J, Schneider A, Long SA, Wei S, Rawlings R, Kinsman M, Evanko SP, **Wight TN**, Greenbaum CJ, Cerosaletti K, Buckner JH. Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression. *Sci Transl Med.* 8:356ra119, 2016. *PMCID: PMC5125295*
327. Reed MJ, Vernon RB, Damodarasamy M, Chan CK, **Wight TN**, Bentov I, Banks WA. Microvasculature of the mouse cerebral cortex exhibits increased accumulation and synthesis of hyaluronan with aging. *J Gerontol A Biol Sci Med Sci.* 72:740-746, 2017. *PMCID: PMC6075594*
328. Balaji S, Wang X, King A, Le LD, Bhattacharya SS, Butte M, Perez VJ, Liechty KW, **Wight TN**, Crombleholme TM, Bollyky P, Keswani SG. Interleukin-10-mediated regenerative postnatal tissue repair is dependent on regulation of hyaluronan metabolism

- via fibroblast-specific STAT3 signaling. *FASEB J.* 31:868-81, 2017. *PMCID: PMC5295728*
329. Kang I, Harten IA, Chang MY, Braun KR, Sheih A, Nivison MP, Johnson PY, Workman G, Kaber G, Evanko SP, Chan CK, Merrilees MJ, Ziegler SF, Kinsella MG, Frevert CW, **Wight TN**. Versican deficiency significantly reduces lung inflammatory response induced by poly I:C stimulation. *J Biol Chem.* 292(1):51-63, 2017. *PMCID: PMC5217699*
330. **Wight TN**. Provisional matrix: A role for versican and hyaluronan. *Matrix Biol.* 60-61:38-56, 2017. *PMCID: PMC5438907*
331. Gaucherand L, Falk BA, Evanko SP, Workman G, Chan CK, **Wight TN**. Crosstalk between T lymphocytes and lung fibroblasts: Generation of a hyaluronan-enriched extracellular matrix adhesive for monocytes. *J Cell Biochem.* 118:2118-2130, 2017. *PMCID: PMC5538566*
332. Keire PA, Kang I, **Wight TN**. Versican: Role in cancer tumorigenesis. In: *Extracellular matrix in tumor biology*. Brekken RA and Stupack DG, eds. *Biology of the Extracellular Matrix*. Cham, Switzerland: Springer International Publishing AG, pp. 51-74, 2017.
333. Dasgupta A, Kjarsgaard M, Capaldi D, Radford K, Aleman F, Boylan C, Altman LC, **Wight TN**, Parraga G, O'Byrne PM, Nair P. A pilot randomized clinical trial of mepolizumab in COPD with eosinophilic bronchitis. *Eur Respir J.* 49:1602486, 2017. *No Federal Support*
334. **Wight TN**, Frevert CW, Debley JS, Reeves SR, Parks WC, Ziegler SF. Interplay of extracellular matrix and leukocytes in lung inflammation. *Cell Immunol.* 312:1-14, 2017. *PMCID: PMC5290208*
335. Kikuchi S, Chen L, Xiong K, Saito Y, Azuma N, Tang G, Sobel M, **Wight TN**, Kenagy RD. Smooth muscle cells of human veins show an increased response to injury at valve sites. *J Vasc Surg.* 67:1556-70, 2018. *PMCID: PMC5740028*
336. Evanko SP, Chan CK, Johnson PY, Frevert CW, **Wight TN**. The biochemistry and immunohistochemistry of versican. *Methods Cell Biol.* 143:261-279, 2018. *PMCID: PMC6419768*
337. Chang MY, Kang I, Gale M Jr, Manicone AM, Kinsella MG, Braun KB, Wigmosta T, Parks WC, Altemeier WA, **Wight TN**, Frevert CW. Versican is produced by Trif- and type I interferon-dependent signaling in macrophages and contributes to fine control of innate immunity in lungs. *Am J Physiol Lung Cell Mol Physiol.* 313:L1069-L1086, 2017. *PMCID: PMC5814701*
338. Nagy N, de la Zerda A, Kaber G, Johnson PY, Hu KH, Kratochvil MJ, Yadava K, Zhao W, Cui Y, Navarro G, Annes JP, **Wight TN**, Heilshorn SC, Bollyky PL, Butte MJ. Hyaluronan content governs tissue stiffness in pancreatic islet inflammation. *J Biol Chem.* 293:567-578, 2018. *PMCID:PMC5767862*
339. Kang I, Chang MY, **Wight TN**, Frevert CW. Proteoglycans as immunomodulators of the innate immune response to lung infection. *J Histochem Cytochem.* 66:241-259, 2018. *PMCID: PMC5958380*
340. **Wight TN**. A role for proteoglycans in vascular disease. *Matrix Biol.* 71-72:396-420, 2018. *PMCID: PMC6110991*

341. Sobel M, Kikuchi S, Chen L, Tang GL, **Wight TN**, Kenagy RD. Clinical factors that influence the cellular responses of saphenous veins used for arterial bypass. *J Vasc Surg.* 68(6S):165S-176S, 2018. *PMCID: PMC6252124*
342. Wall VZ, Barnhart S, Kanter JE, Kramer F, Shimizu-Albergine M, Adhikari N, **Wight TN**, Hall JL, Bornfeldt KE. Smooth muscle glucose metabolism promotes monocyte recruitment and atherosclerosis in a mouse model of metabolic syndrome. *JCI Insight.* 3:e96544, 2018. *PMCID:PMC6124428*
343. Reeves SR, Kang I, Chan CK, Barrow KA, Kolstad TK, White MP, Ziegler SF, **Wight TN**, Debley JS. Asthmatic bronchial epithelial cells promote the establishment of a hyaluronan-enriched, leukocyte-adhesive extracellular matrix by lung fibroblasts. *Respir Res.* 19(1):146, 2018. *PMCID: PMC6090698*
344. **Wight TN**. Editorial: A role for extracellular matrix in atherosclerotic plaque erosion. *J Am Coll Cardiol.* 72(13):1504-1505, 2018.
345. Maisel K, Merrilees MJ, Atochina-Vasserman EN, Lian L, Obratsova K, Rue R, Vasserman AN, Zuo N, Angel LF, Gow AJ, Kang I, **Wight TN**, Eruslanov E, Swartz MA, Krymskaya VP. Immune checkpoint ligand PD-L1 is upregulated in pulmonary lymphangioleiomyomatosis (LAM). *Am J Respir Cell Mol Biol.* 59(6):723-732, 2018. *PMCID: PMC6293078*
346. Kenagy RD, Kikuchi S, Evanko SP, Ruitter MS, Piola M, Longchamp A, Pesce M, Soncini M, Deglise S, Fiore GB, Haefliger JA, Schmidt TA, Majesky MW, Sobel M, **Wight TN**. Versican is differentially regulated in the adventitial and medial layers of human vein grafts. *PLoS One.* 13(9):e0204045, 2018. *PMCID:PMC6161854*
347. Nagy N, Sunkari VG, Kaber G, Hasbun S, Lam DN, Speake C, Sanda S, McLaughlin TL, **Wight TN**, Long SR, Bollyky PL. Hyaluronan levels are increased systemically in human type 2 but not type 1 diabetes independently of glycemic control. *Matrix Biol.* In press, 2018. *PMCID: PMC6401354*
348. Reeves SR, Barrow KA, Kolstad TK, White MP, Rich LM, **Wight TN**, Debley JS. Fibroblast gene expression following asthmatic bronchial epithelial cell conditioning correlates with epithelial donor lung function and exacerbation history. *Sci Rep.* 8:15768, 2018. *PMCID:PMC6202408*
349. Reed MJ, Damodarasamy M, Pathan J, Chan CK, Spiekerman C, **Wight TN**, Banks WA, Day AJ, Vernon RB, Keene CD. Increased hyaluronan and TSG-6 in association with neuropathologic changes of Alzheimer's disease. *J Alzheimers Dis.* 67:91-102, 2019. *PMCID: PMC6398602*
350. Petz A, Grandoch M, Gorski DJ, Abrams M, Piroth MA, Schneckmann R, Homann S, Müller J, Hartwig S, Lehr S, Yamaguchi Y, **Wight TN**, Gorressen S, Ding Z, Kötter S, Krüger M, Heinen A, Kelm M, Gödecke A, Flögel U, Fischer JW. Cardiac hyaluronan synthesis is critically involved in the cardiac macrophage response and promotes healing after ischemia reperfusion injury. *Circ Res.* 124(10):1433-1447, 2019.

BOOKS

1. **Wight TN**, Mecham RP, eds. *The Biology of the Extracellular Matrix: Proteoglycans.* Academic Press, NY, 1987.

NATIONAL AND INTERNATIONAL MEETING PRESENTATIONS

1. "Connective Tissue in Atherogenesis." FASEB Meeting, Atlanta, Georgia, 1981.
2. "Morphology of Proteoglycans." First Latin-American Congress on Cell Biology, Maracaibo, Venezuela, 1983.
3. "Proteoglycans: Structure and Function." American Lung Association Meeting, Anaheim, California, 1985.
4. Session Chair, Gordon Research Conference on Atherosclerosis, June, 1985.
5. "Proteoglycans in Vascular Disease." Medical Colleges of Beijing and Xian, China, October 1985.
6. "Vascular Proteoglycans." Gordon Research Conference, August 1992.
7. "Importance of Proteoglycans in Vascular Tissue." Tissue Engineering, Keystone Symposium, Keystone, CO, April 1991.
8. "Proteoglycans and Atherosclerosis." Workshop on Diabetes and Atherosclerosis, NIH, Bethesda, Maryland, September 1992.
9. "Extracellular Matrix in Aging-Proteoglycans." Sponsored by NIA, Santa Barbara, California, July 1992.
10. "Vascular Proteoglycans." Symposium to Honor Gardiner McMillan, NIH, Bethesda, Maryland, October 1992.
11. "Proteoglycans in Vascular Tissue." British Connective Tissue Society Meeting, London, England, 1991.
12. "Vascular Biology of Proteoglycans." University of Wales, Cardiff, Wales, 1991.
13. "Proteoglycans in Vascular Biology." Glycobiology - New Perspectives on Human Disease, NIH, Bethesda, Maryland, September 1993.
14. "Proteoglycans in Atherosclerosis." 62nd Annual Meeting of Royal College of Physicians and Surgeons of Canada, Vancouver, BC, Canada, September 1993.
15. "Regulation of Proteoglycan Synthesis." American Heart Association Annual Meeting, Atlanta, Georgia, November 1993.
16. "Proteoglycans in Vascular Biology." 22nd Annual Meeting of the Society for Complex Carbohydrates, Puerto Rico, 1993.
17. "Regulation of Proteoglycan Synthesis by Vascular Cells." FASEB Annual Meeting, Anaheim, California, April 1994.
18. "The Biology of Vascular Proteoglycans." Third Brazilian Symposium of Extracellular Matrix, Angros dos Reis, Brazil, September 1994.
19. "Vascular Proteoglycans." International Symposium on Atherosclerosis, Montreal, Canada, October 1994.
20. Session Chair, "Extracellular Matrix in Vascular Biology." American Heart Association Meeting, Dallas, Texas, December 1994.

NATIONAL AND INTERNATIONAL MEETING PRESENTATIONS - Continued

21. "Regulation of Extracellular Matrix Metabolism in Atherosclerosis and Restenosis." Functional and Structural Aspects of the Vascular Wall, American Heart Association Conference, Snowbird, Utah, 1994.
22. "Overview of Proteoglycan Chemistry and Biology." Deuel Conference on Lipids, Monterey, California, 1995.
23. Session Chair, "Extracellular Matrix and Cell Adhesion." FASEB Meeting, Atlanta, Georgia, 1995.
24. "Proteoglycans in Atherosclerosis and Restenosis." Visiting Professor, Department of Bioengineering, Cleveland Clinic, Cleveland, Ohio, May 1996.
25. "Proteoglycans and Restenosis." Restenosis Summit VIII, Cleveland, Ohio, May 1996.
26. "Extracellular Matrix in Atherosclerosis." European Vascular Biology Meeting, Gothenberg, Sweden, June 1996.
27. Session Chair, "Vascular Matrix." IXth International Symposium on Atherosclerosis, Seattle, Washington, September 1996.
28. "Interactions of Lipoproteins with Extracellular Matrix." International Symposium on Nutrition and Atherosclerosis, Shirahama, Japan, December 1996.
29. "Regulation of Smooth Muscle Cell Proteoglycans." Deuel Conference on Lipids, Stevenson, Washington, April 1997.
30. "Extracellular Matrix and Cell Behavior." FASEB Meeting, New Orleans, Louisiana, May 1997.
31. Symposium Chair, "Matrix and Remodeling in Atherogenesis." XIXth Annual Meeting, International Society for Heart Research, Vancouver, BC, Canada, July 1997.
32. "Proteoglycans and Hyaluronan: Regulators of Vascular Cell Phenotype." Vascular Aspects of Ischemic Heart Disease, American Heart Association, Lake Tahoe, Nevada, February 1998.
33. "The Role of Matrix in Post-Angioplasty and Stent Restenosis." Fourth Local Drug Delivery Meeting and Cardiovascular Course, Geneva, Switzerland, February 1998.
34. "Proteoglycans and Hyaluronan: Key Components in Atherosclerosis and Restenosis." Biology of the Vessel Wall, Munster, Germany, September, 1998
35. Session Co-Chair, "Extracellular Matrix." American Heart Association 71st Meeting, Dallas, Texas, November 1998.
36. "Proteoglycans in Vascular Extracellular Matrix." Extracellular Matrix in Diabetes and Atherosclerosis, Seattle, WA, May 1999.
37. "Extracellular Matrix in Vascular Disease." Swedish National Network Cardiovascular Workshop, Gothenberg, Sweden, October, 1999.
38. "Proteoglycans in Restenosis." Sixth Local Drug Delivery Meeting, Geneva, Switzerland, February 2000.

NATIONAL AND INTERNATIONAL MEETING PRESENTATIONS - Continued

39. "Proteoglycans are Key Extracellular Matrix Molecules in Atherosclerosis and Restenosis." Visiting Professor, Cleveland Clinic, Department of Bioengineering, May 2000.
40. "The Importance of Proteoglycans in Atherosclerosis." Maine Medical Center Research Institute, South Portland, Maine, May 2000.
41. "The Role of Proteoglycans in Vascular Disease." American Diabetes Association Annual Meeting, San Antonio, Texas, June 2000.
42. "Proteoglycans: A Modulator of Vascular Pathogenesis." XVth International Congress on Fibrinolysis and Proteolysis, Hamamatsu, Japan, June 2000.
43. "Proteoglycans and Hyaluronan in Atherosclerosis and Restenosis." International Symposium of Atherosclerosis, Stockholm, Sweden, June 2000.
44. "Cell-Mediated Proteoglycan Gene Transfer Alters Vascular Cell Phenotype and the Development of Vascular Lesions." Gordon Research Conference on Proteoglycans, Andover, New Hampshire, July 2000.
45. "Hyaluronan in Atherosclerosis and Restenosis." Hyaluronan 2000, Wrexham, Wales, September 2000.
46. "Proteoglycans are Regulators of Vascular Cell Phenotype." International Congress of Vascular Biology, Geneva, Switzerland, September, 2000.
47. "Importance of Proteoglycans and Hyaluronan in Diabetes." Australian Vascular Biology Meeting, Marysville, Australia, October, 2000.
48. "Proteoglycan and Hyaluronan as Regulators of Vascular Cell Phenotype." Australian Vascular Biology Meeting, Marysville, Australia, October 2000.
49. "Proteoglycans and Hyaluronan are Molecules that Regulate Key Events in Atherosclerosis and Restenosis." Visiting Professor, University of Toronto, March 2001.
50. "Proteoglycans as Regulators of Elastic Fiber Formation." Gordon Research Conference on Elastin & Elastic Fibers, Meriden, New Hampshire, July 2001.
51. "Extracellular Matrix Abnormalities – Clues from the Cardiovascular System." Joint Workshop on Hutchinson-Gilford Progeria Syndrome, NIH, Bethesda, Maryland, November 2001.
52. "Lung Remodeling in Asthma." Northwest Asthma and Allergy Meeting, Glaxo SmithKline, Phoenix, Arizona, February 2002.
53. "Proteoglycans in Atherosclerosis and Restenosis." XIIth International Vascular Biology Meeting, Karuizawa, Japan, May 2002.
54. "Proteoglycans and Hyaluronan and the Vascular Complications of Diabetes." Diabetes Endocrinology Research Center Symposium, University of Washington, Seattle, Washington, May 2002.
55. "Use of Proteoglycan Genes for the Creation of Elastic Tissue Sheets and Small Caliber Prosthetic Vessels." Gordon Research Conference on Proteoglycans, Andover, New Hampshire, July 2002.

NATIONAL AND INTERNATIONAL MEETING PRESENTATIONS - Continued

56. “Cardiovascular Uses for Hyaluronan Oligosaccharides.” Hyaluronan Oligosaccharide Workshop, Woods Hole, Massachusetts, July 2002.
57. “Role of Hyaluronan in Atherosclerosis and Restenosis.” American Heart Association Workshop on Extracellular Matrix,” Chicago, Illinois, November, 2002.
58. “Hyaluronan in the Cardiovascular System.” Hyaluronan Conversations Workshop, St. Tropez, France, June 2003.
59. “Elastin-Proteoglycan Interactions.” Gordon Research Conference on Elastin & Elastic Fibers, Meriden, New Hampshire, August, 2003.
60. “Proteoglycans in Cardiovascular Disease.” Pathobiology of Proteoglycans, Parma, Italy, September, 2003.
61. “The Pro-Inflammatory Nature of the Extracellular Matrix.” XIIIth International Symposium on Atherosclerosis, Kyoto, Japan, September, 2003.
62. “Hyaluronan in the Cardiovascular System.” Hyaluronan 2003, Cleveland, Ohio, October, 2003.
63. “Use of Hyaluronan Oligosaccharides in Cardiovascular Disease.” Hyaluronan Oligosaccharide Workshop, Cleveland, Ohio, October, 2003.
64. “The Importance of Extracellular Matrix Proteoglycans in Atherosclerosis and Restenosis.” 44th Annual Meeting of the Japanese College of Angiology, Fukuoka, Japan, November, 2003.
65. “The Response to Retention Hypothesis of Atherosclerosis: Is there a Universal Theme?” 44th Annual Meeting of the Japanese College of Angiology, Fukuoka, Japan, November, 2003.
66. “The Use of Proteoglycan Genes to Engineer Vascular Tissue.” 8th Annual Workshop at Hilton Head on Cardiovascular Tissue Engineering, Hilton Head, South Carolina, March, 2004
67. Chair, “Cell Matrix Interactions.” The 18th International Vascular Biology Meeting, Toronto, Canada, June, 2004.
68. “Versican or Versicant: Key Regulators of Vascular Cell Phenotype.” Gordon Conference on Proteoglycans, Andover, New Hampshire, July, 2004.
69. Co-Chair and Speaker, “Extracellular Matrix and Inflammation.” 12th International Congress of Histochemistry and Cytochemistry, San Diego, California, July, 2004.
70. Co-Chair, “Versican – Master Regulation of Vascular Cell Phenotype and Extracellular Matrix Assembly,” American Society for Matrix Biology, San Diego, California, November, 2004.
71. Panel Discussant, “Tissue Engineering: Where in the World, Will We Get the Cells?” Engineering Tissues, Hilton Head Workshop, Hilton Head, South Carolina, March 2005.
72. “Proteoglycans, Cells and Elastogenesis.” Gordon Conference on Elastin & Elastic Fibers, Waterville Valley, New Hampshire, July 2005.

NATIONAL AND INTERNATIONAL MEETING PRESENTATIONS - Continued

73. "Extracellular Matrix." Workshop on Vulnerable Atherosclerotic Plaque, NIH, Bethesda, Maryland, September, 2005.
74. "Lung Extracellular Matrix: Alterations in Response to Enantiomers of Albuterol." Scientific Forum, Sepracor, Boston, Massachusetts, September 2005.
75. "Versican in Atherosclerosis and Restenosis." American Heart Association Meeting, Dallas, Texas, November 2005.
76. "Proteoglycans." 4th International Vulnerable Plaque Meeting, Capri, Italy, May 2006.
77. "Hyaluronan and Versican: Partners in Crime in Vascular Disease." Extracellular Glycomatrix in Health and Disease, Awaji Island, Japan, June 2006.
78. "The Pro-Inflammatory Nature of the Extracellular Matrix." Satellite Meeting – New Developments in Atherosclerosis Research in Pharmaceutical Sciences, Kameoka, Japan, June 2006.
79. Conference Vice-Chair, Gordon Research Conference on Proteoglycans, Andover, New Hampshire, July 2006.
80. Session Chair, "Proteoglycans in Injury and Inflammation." Gordon Research Conference on Proteoglycans." Andover, New Hampshire, July 2006.
81. Session Co-Moderator, "Natural History of Atherosclerosis." American Heart Association Meeting, Chicago, Illinois, November 2006.
82. Session Co-Moderator, "Extracellular Matrix in Vascular Remodeling." American Heart Association Meeting, Chicago, Illinois, November 2006.
83. "Lung Extracellular Matrix in Asthma: Alterations in Response to Enantiomers of Albuterol" , Sepracor Scientific Forum, Naples, FL, February 2007
84. Session Co-Chair at the Annual Hilton Head Workshop, Engineering Tissues: Replace, Repair, Regenerate, Hilton Head, SC, March, 2007.
85. "The use of proteoglycan genes to engineer extracellular matrix assembly." Vascular Matrix Biology and Bioengineering Workshop, Whistler, BC, March 2007.
86. Session Chair, "Vascular Matrix in Disease." Vascular Matrix Biology and Bioengineering Workshop, Whistler, BC, March 2007.
87. "Proteoglycans as Therapy," 5th International Vulnerable Plaque Meeting, Santorini, Greece, June 2007.
88. "Arterial Remodeling in Vascular Disease: A Key Role for Hyaluronan and Versican," Inaugural International Conference in Cerebrovascular Disease, Manchester, UK, July 2007.
89. Session Chair, "Adipose Tissue, Inflammation and Vascular Risk," American Heart Association Meeting, Orlando, FL, November 2007.
90. "Models for Generating Tissue-Engineered Blood Vessels," American Heart Association Meeting, Orlando, FL, November 2007.

NATIONAL AND INTERNATIONAL MEETING PRESENTATIONS - Continued

91. "Hyaluronan and Versican: Regulators of Key Inflammatory Events in Vascular Disease," Invited Faculty and Speaker at 4th Finnish Glycoscience Graduate Course and Meeting, Rautavaara, Finland, November 2007.
92. "Pancreatic Extracellular Matrix in Autoimmune Disease," Autoimmunity Prevention Center Meeting (NIH), Stanford University School of Medicine, Palo Alto, CA, March 2008.
93. Session Chair, "Laser Capture Microdissection for Molecular Analysis," Experimental Biology Annual Meeting, San Diego, CA, April 2008.
94. "Extracellular Matrix as a Target for Therapeutic Intervention," 6th International Vulnerable Plaque Meeting, Vouliagmeni, Greece, June 2008.
95. "The Importance of Extracellular Matrix in the Progression and Regression of Atherosclerotic Lesions," 11th Cardiovascular Genomics and Atherosclerosis Symposium, Seoul, South Korea, October 2008.
96. Session Chair, "Extracellular Matrix and Cardiovascular Disease," American Heart Association Annual Meeting, New Orleans, November 2008.
97. Session Chair, "Matrix Signaling," Vascular Matrix Biology and Bioengineering Workshop II, Whistler, BC, March 2009.
98. Session Chair, "Cardiovascular Tissue Engineering," American Heart Association, Orlando FL, November, 2009.
99. "Importance of the Extracellular Matrix in the Pathogenesis of Cardiovascular Disease," at The Progeria Research Foundation's 10th Anniversary Workshop on Progeria, "From Bench to Bedside in a Decade," Boston, MA, April 2010.
100. Session Chair, "Cardiovascular and Lymphomyeloid Systems," International Society for Hyaluronan Sciences, 8th International Conference, Kyoto, Japan, June 2010.
101. Session Chair, "Cardiovascular," Proteoglycan Gordon Conference, Andover, NH, July 2010.
102. Guest Faculty, "The Extracellular Matrix: Active or Passive Player in Fibrosis?," International Summit of Fibrosis in Intestinal Inflammation: Mechanisms and Biological Therapies, Cleveland Clinic, Cleveland, OH, September 2010.
103. "Versican and Hyaluronan are Key Components in the Development of Cardiovascular Disease," 2010 International Workshop of Glycobiology: Glycan Function and the Application. Shanghai, China, October 2010.
104. "The Biomatrix and the Control of Vascular Cell Phenotype," International Conference on the Structure and Function of Biomatrix: How Biomatrix Controls Cell Function and Gene Expression. Budapest, Hungary, July 2011.
105. Visiting Scholar, "Versican in the Extracellular Matrix and the Control of Inflammation," Lerner Institute, Cleveland Clinic "Program of Excellence in Glycoscience," Cleveland, OH, May, 2012.

NATIONAL AND INTERNATIONAL MEETING PRESENTATIONS - Continued

106. Keynote Speaker, "Extracellular Matrix and the Control of Immunity and Inflammation," 17th Annual Workshop, Regenerative Medicine: Technologies Enabling Novel Therapies, Hilton Head, SC, March 2013.
107. Speaker, "Extracellular Matrix and the Control of Cell Phenotype," Short Course: "ECM in Regenerative Medicine: What is the Matrix? The answer is out there and looking for you!" 17th Annual Workshop, Regenerative Medicine: Technologies Enabling Novel Therapies, Hilton Head, SC, March 2013.
108. Invited Speaker, "Versican Regulates the Binding of Leukocytes to Hyaluronan and Influences Events in Immunity and Inflammation," and Session Chair, Annual Meeting of the International Society of Hyaluronan Sciences, Oklahoma City, OK, June 2013.
109. Invited Speaker, "Targeting Versican and the Control of Inflammation," 8th International Conference on Proteoglycans, Frankfurt, Germany, August 2013.
110. Invited Speaker, "Versican and the Control of Cell Phenotype in Disease," Federation of European Biochemical Societies (FEBS) Advanced Lecture Course, "Matrix Pathobiology, Signaling and Molecular Targets," Kos, Greece, September - October 2013.
111. Invited Speaker, "Hyaluronan and Friends: Key Matrix Components Regulating Cell Phenotype in Disease," Targeting Hyaluronan in Pathophysiology and Disease, Düsseldorf, Germany, January 2014.
112. Invited Speaker, Annual Meeting of the Network for Pancreatic Organ Donors with Diabetes (nPOD), Atlantic Beach, FL, February 2014.
113. Session Chair, Biologic Scaffolds for Regenerative Medicine, Napa, CA, April 2014.
114. Invited Speaker, "Hyaluronan Binding Proteins," American Society for Matrix Biology Biennial Meeting, Cleveland, OH, October 2014.
115. Session Chair, "Extracellular Matrix Working Group," Annual Meeting of the Network for Pancreatic Organ Donors with Diabetes (nPOD), Miami, FL, February 2016.
116. Ninth Symposium on Biological Scaffolds for Regenerative Medicine, Napa, CA, April 2016.
117. Co-Chair of the Extracellular Matrix Biology Session, International Vascular Biology Meeting (IVBM), Boston, MA, October 2016.
118. Invited Speaker, "Hyaluronan and Friends: Regulators of Cell Phenotype in Chronic Disease," and Session Chair, "Hyaluronan in Chronic Disease Processes," 11th Annual Conference of the International Society of Hyaluronan Sciences, Cleveland, OH, June 2017.

INVITED RESEARCH SEMINARS

1. Cornell University Medical School, New York, NY, November 1982
2. Boston University School of Medicine, Boston, MA, May 1982
3. NIDR, Bethesda, MD, September 1985
4. Rush Presbyterian - St. Luke's Medical Center, Chicago, IL, November 1985
5. Cornell University Medical School, New York, NY, November 1987
6. La Jolla Cancer Center, La Jolla, CA, October 1987
7. Jefferson Medical College, Philadelphia, PA, May 1989
8. Merck, Sharpe and Dohme, Rahway, NJ, May 1989
9. University of Alabama, Birmingham, AL, May 1989
10. Washington University, St. Louis, MO, June 1990
11. Telios Pharmaceuticals, La Jolla, CA, April 1993
12. University of Minnesota, Minneapolis, MN, March 1993
13. University of British Columbia, Vancouver, B.C., September 1994
14. Thomas Jefferson University, Philadelphia, PA, October 1994
15. Gladstone Foundation, San Francisco, CA, May 1995
16. Cleveland Clinic, Cleveland, OH, October 1996
17. University of Michigan, Ann Arbor, MI, September 1997
18. Parke-Davis, Ann Arbor, MI, September 1997
19. Gladstone Foundation, San Francisco, CA, January 1998
20. Institute of Atherosclerosis Research, Munster, Germany, September, 1998
21. Karolinska Institute, Stockholm, Sweden, October, 1999
22. Wallenberg Cardiovascular Laboratories, Gothenberg, Sweden, October, 1999
23. Research Servier, Suresnes, France, February 2000
24. University of Zurich, Zurich, Switzerland, February 2000
25. University of Washington, Department of Pathology, March 2000
26. Department of Biochemistry, University of Kanazawa, Japan, June, 2000
27. Armed Forces Institute of Pathology, Washington, DC, June 2000
28. Columbia University, Department of Medicine, New York, NY, December 2000
29. Cornell Medical College, Department of Pathology, New York, NY, December 2000
30. Abbott Laboratories, Chicago, IL, May 2001
31. Guidant Corporation, San Francisco, CA, June 2001
32. Boston Scientific, Minneapolis, MN, August 2001

33. Medical University of South Carolina, SC, October 2001
34. Georgia Tech School of Biomedical Engineering, Atlanta, GA, January 2002.
35. Center for Extracellular Matrix Biology, Texas A and M University, April 2003
36. Tufts School of Medicine, Boston, Massachusetts, May 2003
37. Cleveland Clinic, Cleveland, Ohio, May 2003
38. Berlex, San Francisco, California, July 2003
39. University of Toronto, Department of Biochemistry, July 2003
40. EPIX Medical, Cambridge, Massachusetts, August 2003
41. University of Minnesota, Dept. of Pathology and Laboratory Medicine, December 2003
42. University of Washington, Department of Pulmonary and Critical Care, January, 2004
43. University of Washington, Department of Bioengineering, February 2004
44. University of Iowa, Department of Medicine, February, 2004
45. Benaroya Research Institute, Seattle, Washington, March 2004
46. Astra Zeneca, Gothenberg, Sweden, April 2004
47. University of Kentucky (Visiting Professor) October 2004
48. Northwestern University, Evanston, Illinois, April 2005
49. Harvard Medical School, Department of Pathology, Boston, Massachusetts, January 2006
50. University of Utrecht School of Veterinary Medicine, The Netherlands, March 2006
51. University of Dusseldorf, Department of Pharmacology, Germany, March 2006
52. Boston University, Department of Biochemistry, Massachusetts, March 2006
53. Boston Biomedical Institute, Watertown, Massachusetts, March 2006
54. Lilly Corporate Center, Indianapolis, Indiana, May 2006
55. University of Washington, Department of Regenerative Medicine, Seattle, May 2006
56. Hokuriku University, Kanazawa, Japan, June 2006
57. Grand Rounds, Virginia Mason Medical Center, Seattle, Washington, June 2006
58. University of Washington, Biomaterials Short Course, Seattle, February, 2007
59. Cornell University, Weill Medical College, March, 2007
60. Division of Preventive Medicine and Nutrition, Columbia University, March, 2007
61. Strang Cancer Prevention Center, The Rockefeller University, March, 2007
62. Cleveland Clinic, Cleveland, Ohio, May, 2007
63. Welcome Trust Center for Cell-Matrix Research, Manchester, UK, July 2007
65. Department of Pathology, University of Washington, Seattle, July 2007
66. Excellence Cluster Cardio-Pulmonary System Seminar Series, Bad Nauheim, Germany, September 2007

67. Department of Bioengineering, Rice University, Houston, TX, October 2007
68. Department of Medicine, Turku University Central Hospital, Turku, Finland, December 2007
69. Johnson & Johnson, Princeton, NJ, January 2008
70. Genzyme Inc., Framingham, MA, April 2008
71. Cardiovascular Center, University of Washington, Seattle, WA, May 2009
72. Department of Cell Biology & Physiology, Washington University, St. Louis, MO, September 2009
73. Karolinska Institute, Stockholm, Sweden, December 2009
74. University of Kuopio, Kuopio, Finland, December 2009
75. Cell & Developmental Biology, Weill Cornell Medical College, New York, NY, December 2010
76. Engineered Biomaterials, University of Washington, Seattle, WA, February 2011
77. Physiology & Experimental Medicine, Hospital for Sick Children, Toronto, Canada, April 2011
78. The Center for Cardiovascular Biology, University of Washington, Seattle, WA, May 2011
79. CV Path, Gaithersburg, MD, May, 2012
80. Section of Comparative Medicine, Yale University, New Haven, CT, June 2012
81. University of Manchester, UK, September 2013
82. Grand Rounds, University of Minnesota, Minneapolis, March 2014
82. Zymogenetics, Seattle, WA, March 2014
83. Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, March 2015
84. Department of Bioengineering, University of Washington, Seattle, WA, May 2015
85. Center for Cardiovascular Diseases and Sciences, Louisiana State University Health Sciences Center-Shreveport, LA, October 2015
86. Cooperative Study Group for Autoimmune Disease Prevention, NIAID, NIH, Bethesda, MD, October 2015.
87. Seattle Children's Research Institute, Seattle, WA, November 2015
88. Department of Experimental Medical Science, Lund University, Lund, Sweden, September 2016
89. Vascular Biology Seminar, University of California, Los Angeles, October 2016

ABSTRACTS (Selected)

1. **Wight TN**, Cooke PH, Smith SM. An electron microscopic study of developing pigeon aorta cell *in vitro*. *J Cell Biol* 67:2, 1975.
2. Curwen KD, **Wight TN**. Similarities in glycosaminoglycan content of pigeon arteries and arterial cell cultures. *J Cell Biol* 75(2), 1977.
3. Harris S, Gajdusek C, Schwartz S, **Wight T**. Role of endothelial cell products in vascular growth responses and neovascularization. *J Cell Biol* 83(2):118a, 1979.
4. Tveter-Gallagher E, **Wight TN**, Cheney D. Effects of the phycocolloid carrageenan on human fibroblasts *in vitro*. A preliminary study. *J Cell Biol* 83(2):118a, 1979.
5. **Wight TN**, Curwen KD, Homan W, Minick C. Effect of regenerated endothelium on glycosaminoglycan accumulation in the arterial wall. *Fed Proc* 38(3):1075, 1979.
6. **Wight TN**, Hascall VC, Ross R. Synthesis and secretion of proteoglycans by primate arterial smooth muscle cells during growth stimulation *in vitro*. *J Cell Biol* 87(2)119a, 1980.
7. Iozzo RV, **Wight TN**, Bolender RP. Integrated biochemical and sterological analysis of proteoglycans in the intercellular matrix of human colon carcinoma. *J Cell Biol* 87(2)123a, 1980.
8. Iozzo RV, Armstrong C, **Wight TN**. Biochemical and ultrastructural studies of proteoglycans in human colon carcinoma. *Fed Proc* 39(4):1019, 1980.
9. Oohira A, **Wight TN**, McPherson J, Bornstein P. Biochemical and ultrastructural studies of proteo-heparan sulfates synthesized by PYS-2, a basement membrane producing cell line. *J Cell Biol* 9(12):162a, 1981.
10. Schmidt R, **Wight TN**, Habenicht A, Glomset J, Ross R. Maintenance of 3T3 cell shape requires mevalonic acid. *J Cell Biol* 91(2):297a, 1981.
11. **Wight TN**, Hascall VC, Ross R. The synthesis and secretion of proteoglycans by arterial smooth muscle cells cultured from nonhuman primates. *Fed Proc* 41(3):269, 1982.
12. Clowes AW, Clowes MM, Gown AM, **Wight TN**. Distribution of proteoheparan sulfate in rat aorta. *Fed Proc* 41(3):441, 1982.
13. Iozzo RV, Carns JL, Poole AR, Rosenberg L, **Wight TN**. Immunochemical localization of various proteoglycans in human colon and colon carcinoma. *Fed Proc* 41(3):616, 1982.
14. Oohira A, **Wight TN**, Bornstein P. Synthesis of proteoglycans by vascular endothelial cells. *Fed Proc* 41(3):864, 1982.
15. Marroquin R, Iozzo RV, Birdsell D, **Wight TN**. Analysis of proteoglycans by high PLC. *Fed Proc* 41(4):1438, 1982.
16. Kinsella MG, **Wight TN**. Modulation of sulfated proteoglycan metabolism by cultured aortic endothelial cells during migration. *J Cell Biol* 99(4):173a, 1984.
17. Lark MW, **Wight TN**. Effect of a collagenous extracellular matrix on proteoglycan metabolism by aortic smooth muscle cells. *J Cell Biol* 99(4):174a, 1984.

ABSTRACTS (Selected) - continued

18. Garrigues HJ, Lark MW, Hellström KE, **Wight TN**. Chondroitin sulfate proteoglycan as a marker for melanoma. *J Cell Biol* 99(4):386a, 1984.
19. Lark MW, Hellström I, Hellström KE, **Wight TN**. Characterization of a monoclonal antibody directed against arterial wall chondroitin sulfate proteoglycan. *J Cell Biol* 101(5):337a, 1985.
20. Kinsella MF, **Wight TN**. Structure and metabolism of sulfated proteoglycan in wounded and confluent cultures of bovine aortic endothelial cells. *J Cell Biol* 101(5):338a, 1985.
21. Snow AD, Mar H, Nochlin D, **Wight TN**. Corpora amylacea in aging and Alzheimer's brain contains antigenic sites for chondroitin sulfate and heparan sulfate proteoglycans. Vth International Symposium on Amyloidosis, 1987.
22. Snow AD, Kisilevsky R, **Wight TN**. Immunolocalization of heparan sulfate proteoglycans to AA amyloid deposition sites in spleen during experimental amyloidosis. Vth International Symposium of Amyloidosis, 1987.
23. Juul SE, Hodson WA, **Wight TN**. Proteoglycan changes with development in the non-human primate (*Macaca nemestrina*) lung. *J Cell Biol* 109:233a, 1989.
24. Järveläinen H, Kinsella MG, Sandell LJ, **Wight TN**. The small dermatan sulfate proteoglycan II (PG-II) is expressed by bovine arterial smooth muscle cells but not by endothelial cells. *J Cell Biol* 109:233a, 1989.
25. Schönherr E, Sandell LJ, **Wight TN**. Differential effect of PDGF and TGF- β on proteoglycan and DNA synthesis by cultured arterial smooth muscle cells and chondrocytes. *J Cell Biol* 109:234a, 1989.
26. Kaplan ED, **Wight TN**. Differential expression of tenasin isoforms during human skin development. *ASCB Abstracts*, 1994.
27. Olin KL, Chait AC, **Wight TN**. Lipoprotein lipase enhances the binding of native and oxidized low density lipoproteins to biglycan and versican. *Circulation* 96S:I-40, 1996.
28. Fischer JW, Davies MG, **Wight TN**, Clowes AW. Versican is the predominant proteoglycan in flow accelerated neointimal hyperplasia of endothelialized baboon vascular grafts. *Circulation* 98S: I-228, 1998.
29. Boren J, Olin KL, Arnold KS, Ludwig EH, **Wight TN**, Chait AC, Innerarity T. Engineering non-atherogenic low density lipoproteins – direct evidence for the response to retention hypothesis. *Circulation* 98S: I-314, 1998.
30. Olin KL, Kunjathor VV, DeBeer F, **Wight TN**, Chait A, LeBoeuf RC, O'Brien KD. Co-localization of serum amyloid A with apolipoprotein A-1 and perlecan in lesions of atherosclerosis-prone mice. *Circulation* 100S: I-400, 1999.
31. Olin KL, Benton JL, Rutledge JM, O'Brien KD, **Wight TN**, Chait A. ApoE facilitates the retention of HDL on extracellular matrix *in vitro* and on murine carotid arteries *in situ*. *Circulation* 100S: I-539, 1999.
32. Olin KL, Krauss RM, La Belle M, Hokanson JE, **Wight TN**, Chait A. ApoCIII modulates lipoprotein binding to the vascular proteoglycan, biglycan. *Circulation* 100S: I-693, 1999.

ABSTRACTS (Selected) - continued

33. Olin KL, O'Brien, KD, DeBeer F, Kindy MS, **Wight TN**, Chait A. Serum amyloid A mediates the binding of HDL to vascular proteoglycans. *Circulation* 100S: I-706, 1999
34. Davies MG, Fischer JW, Kenagy R, **Wight TN**, Clowes AW. Time course of flow induced neointimal atrophy in endothelialized baboon vascular grafts. *Circulation* 100S: I-708, 1999.
35. Evanko SP, **Wight TN**. Critical roles of hyaluronan and versican during proliferation of vascular smooth muscle cells. *Circulation* 100S: I708, 1999.
36. Fischer JW, Kinsella MG, Clowes MM, Clowes AW, **Wight TN**. Local expression of bovine decorin reduces neointima formation after arterial injury in rats. *Circulation* 100S: I-753, 1999.
37. Altman LC, Chan CK, Perigo S, Braun K, Johnson PY, **Wight TN**. Accumulation of the extracellular matrix (ECM) components, hyaluronan and versican in human lung cell cultures is modulated differently by R- and S-isomers of albuterol. *J Allergy Clin Immunol* 121(2, S1):S121, 2008.
38. Johnson PY, Perigo S, Braun K, Chan CK, Altman LC, **Wight TN**. Leukotriene D4 (LTD4), EGF and TGF β interact synergistically to increase the accumulation of the extracellular matrix component, hyaluronan, in cultured human lung fibroblast cultures (HLF). *J Allergy Clin Immunol* 121(2, S1):S121, 2008.
39. Perigo S., Braun K, Chan CK, Johnson PY, Altman LC, **Wight TN**. Hyaluronan turnover in the extracellular matrix (ECM) is reduced in human lung fibroblasts (HLF) treated with the viral mimetic, poly I:C. *J Allergy Clin Immunol* 121(2, S1):S200, 2008.
40. Bollyky P, Falk B, Pickett M, Nepom G, **Wight T**. Tonic for T-cells: hyaluronan promotes STAT5 signaling in the absence of IL-2. *Glycobiology* 22(11):1539, 2012.
41. Kang I, Yoon D, Braun K, **Wight T**. Expression of V3 versican in arterial smooth muscle cells reprograms cellphenotypes by modulating TGF- β -and EGF-induced signaling pathways. *Glycobiology* 22(11):1522, 2012.
42. Nagy N, Kaber G, Campbell DJ, **Wight TN**. Type 1 diabetes: Involvement of the extracellular matrix in immune-mediated pancreatic islet destruction. *Glycobiology* 22(11):1568, 2012.
43. Kang I, Yoon D, Braun KR, **Wight TN**. Expressing V3 versican upregulates tropoelastin levels while reducing proinflammatory cell adhesion molecules of arterial smooth muscle cells by modulating TGF- β - and EGF-induced signaling pathways. American Society for Matrix Biology, San Diego, CA, November 2012.
44. Kang I, Barth JL, Sproul E, Yoon D, Braun KR, Argraves WS, **Wight TN**. Expression of versican isoforms in the control of inflammatory arterial smooth muscle cell phenotype. Proteoglycan Gordon Research Conference, Andover, NH, July 2014.
45. Reeves SR, Kang I, Kolstad TK, Gallaher A, **Wight TN**, Debley JS. Expression of hyaluronan synthases and hyaluronidases by lung fibroblasts is differentially regulated by bronchial epithelial cells from asthmatic children and altered by RSV infection. *Am J Respir Crit Care Med*. 191:2015, A2068, 2015.

ABSTRACTS (Selected) – continued

46. Kang I, Harten IA, Kaber G, Keire PA, Merrilees MJ, **Wight TN**. A Role for Versican in Engineered Tissues: Modulating Elasticity and Inflammation. 9th Symposium on Biologic Scaffolds for Regenerative Medicine, Napa, CA, April, 2016.
47. Kang I, Harten IA, Kaber G, Shieh A, Nivison MP, Workman G, Chan CK, Merrilees MJ, Ziegler SF, Frevert CW, **Wight TN**. Versican deficiency significantly reduces inflammatory response in the lungs induced by poly I:C stimulation. Proteoglycan Gordon Research Conference, Andover, NH, July 2016.
48. Reeves SR, Chan CK, Barrow KA, Kang I, Kolstad TK, White MP, **Wight TN**, Debley JS. Extracellular matrix generated by human lung fibroblasts co-cultured with asthmatic airway epithelial cells displays enhanced leukocyte adhesion. International Society of Hyaluronan Sciences, 11th Conference, Cleveland, OH, June 2017.
49. Kang I, Gaucherand L, Falk BA, Chan CK, Workman G, Boyle DL, Firestein GS, MacDonald KM, **Wight TN**. The pathogenic roles of the extracellular matrix in rheumatoid arthritis. 3rd Annual Clinical and Translational Research Symposium, Benaroya Research Institute at Virginia Mason, Seattle, WA, September 2017.
50. Reeves SR, Kang I, Barrow KA, White MP, **Wight TN**, Debley JS. Hyaluronan dependent leukocyte adhesion is enhanced by viral infection, but not by aeroallergen exposure in human lung fibroblasts. American Thoracic Society 2018 International Conference, May 18-23, 2018 - San Diego, CA. *Am J Respir Crit Care Med*. 197:A2857, 2018.
51. Wang X, Balaji S, Steen E, Li H, Blum A, Bollyky P, **Wight T**, Keswani S. Regulation of hyaluronan deposition abates tubulointerstitial fibrosis in ureteral obstruction. Proteoglycans Gordon Research Conference, Andover, NH, July 2018.
52. Kang I, Hundhausen C, Evanko SP, Gaucherand L, Harten IA, Firestein GS, Boyle DL, MacDonald K, Buckner JH, **Wight TN**. Crosstalk between CD4 T lymphocytes and stromal cells generates immunoregulatory extracellular matrix enriched in hyaluronan. Proteoglycans Gordon Research Conference, Andover, NH, July 2018.
53. Harten IA, Kaber G, Agarwal KJ, Kang I, Ibarrientos SR, Workman G, Chan CK, Nivison MP, Kinsella MG, **Wight TN**. N-linked glycosylation of versican isoform V3 is critical for its solubility and secretion. Proteoglycans Gordon Research Conference, Andover, NH, July 2018.
54. Chang MY, Nolin JD, Brune J, Johnson BW, Larmore MJ, **Wight TN**, Altemeier WA, Hallstrand TS, Frevert CW. Mechanism of Increased Versican Expression in Inflammatory Airway Disease. Proteoglycans Gordon Research Conference, Andover, NH, July 2018.

PARTICIPATING MEMBER OF THE FOLLOWING TRAINING GRANTS

5T32 HL007312	Experimental Pathology of Cardiovascular Disease 1983 - present (PI: S. Schwartz)
5T32 HL007028	Nutrition, Obesity, and Atherosclerosis 2008 - present (PI: K. Bornfeldt)
5T32 AG000057	Genetic Approaches to Aging Research 1983 - present (PI: P. Rabinovitch)
5T32 DK007247	Diabetes, Obesity, and Metabolism 1998 - present (PI: S. Kahn)
5T32 HL007287	Pulmonary and Critical Care Medicine Research Training Grant 2010 - present (PI: R.W. Glenny)
5T32 GM007266:	Medical Scientist Training Program 1984 - 2009 (PI: L. Loeb)

OTHER PROGRAMMATIC AFFILIATIONS

Affiliate Investigator, Diabetes Research Center, UW	2003 – 2018
Affiliate Faculty, Institute for Stem Cell and Regenerative Medicine (ISCRM), UW	2006 – present
Network for Pancreatic Organ Donors with Diabetes (nPOD)	2010 – present
Affiliate Faculty, UW Medicine Diabetes Institute	2019 – present

TRAINEES**Ph.D. Thesis Committee**

Ms. Robin Heller-Harrison	Pathobiology/UW	1980 - 1985
Mr. Everett Nichols	Pathobiology/UW	1982 - 1986
Ms. Susanne Mumby	Biochemistry/UW	1982 - 1984
Mr. Jacques Garrigues	Pathology (Chairman)/UW	1983 - 1988
Mr. Russell Faust	Pathology/UW	1986 - 1988
Ms. Arlene Wechezak	Pathology (Chairman)/UW	1985 - 1989
Mr. Mark Robinson	Biostructure/UW	1982 - 1985
Mr. Rod Schmidt	Biochemistry/UW	1982 - 1985
Ms. Eileen Bryant	Pathology/UW	1979 - 1981
Mr. Howard Coleman	Pathology/UW	1987 - 1990
Mr. Paul Andreassen	Pathology/UW	1987 - 1992
Mr. Steven Chessler	Pathology/UW	1989 - 1992
Ms. Elizabeth Ann Everitt	Biological Structure/UW	1989 - 1992
Mr. Timothy Scranton	Biophysics and Physiology/UW	1991 - 1995
Mr. Terry LaBell	Pathology/UW	1991 - 1995
Ms. Janice Benson	Biological Structure/UW	1992 - 1995

Mr. Larry Chun	Biological Structure/UW	1991 - 1995
Ms. Beth Kaplan	Biological Structure (Chair) /UW	1992 - 1996
Mr. James Pace	Pathology/UW	1997 - 2001
Ms. Michel Gooden	Biological Structure/UW	1998 - 2000
Ms. Joell Solan	Pathobiology/UW	1999 - 2002
Ms. Gabriella Curinga	Pathology/UW	2000 - 2004
Mr. Paul Keire	Pathology (Chairman)/UW	2001 - 2009
Mr. David Wu	Pathobiology, Univ. of Toronto (External Examiner)	2003
Mr. Kin Chan	Molecular & Cellular Biology/UW	2003 - 2008
Ms. Karin Tran-Lundmark	Vascular Surgery/Karolinska Institute Sweden (Co-supervisor – external)	2003 - 2008
Ms. Ingrid Harten	Pathology (Chairman)/UW	2004 - 2011
Mr. Thomas Robey	Bioengineering/Pathology/UW	2004 - 2007
Ms. JoSette Broiles	Bioengineering/Georgia Tech University	2003 - 2007
Ms. Ildiko Erdelyi	Pathology/University of Utrecht, The Netherlands (Co-Chair)	2004 - 2005
Mr. David Allison	Bioengineering/Rice University	2006 - 2008
Ms. Anne Kultti	Institute of Biomedicine/University of Kuopio/Finland (Opponent)	2009
Ms. Mary Nivison	Pathology/UW	2010 - 2013
Ms. Autumn Tocchi	Pathology/UW	2013 -
Ms. Fui Jiun Choong	Immunology/The Australian National University (International Examiner)	2013
Ms. Alyssa Sheih	Immunology/UW	2015
Mr. Ville Koistinen	Biomedicine/University of Eastern Finland	2017
Mr. Chun Yi Ng	Medicine/Sydney Medical School, University of Sydney, Australia	2018

Master of Science Thesis Committee

Mr. Michael McNutt	Pathology/UW	1983 - 1985
Mr. Ray Esclamado	Otolaryngology/UW	1984 - 1984
Mr. Ed Ricciardelli	Otolaryngology/UW	1986 - 1988
Mr. Andrew Nelson	Pathology/UW	1979 - 1985
Mr. Daniel Harrah	Pathology (Chairman)/UW	1983 - 1989

Medical Student Summer Research Training or Undergraduate Research Training

Mr. Jeff Stickney	UW	1983
Mr. Darren Hollenbaum	UW	1986
Mr. Scott Isenath	UW	1999

Visiting Student Research Training

Kiet Tran	Karolinska University, Sweden	1998 - 1999, 2004
Karin Lundmark	Karolinska University, Sweden	1999, 2004
Ms. Rebecca Zuanich	University of Washington	2001
Stephanie de Dios	Monash University, Melbourne, Australia	2001

Montse Serra Muxi	Universitat Autònoma de Barcelona, Spain	2001
Julie Nigro	Monash University, Melbourne, Australia	2002
Robert Huang	University of Auckland, Auckland, New Zealand	2003
Ildiko Erdelyi	Utrecht University, The Netherlands	2004
Daniel Hernandez	University of Barcelona, Spain	2005
Melanie Ivey	Baker Institute, Monash University, Australia	2005
Stanley Okoro	Physician Scientist Training Program	2009
Katharina Röck	Universität Duisburg-Essen, Germany	2009
Francisca Diaz Perez	Medical University of Graz, Austria	2014
Ya-Ting Chang	Karolinska University, Sweden	2014
Oscar van der Have	Lund University, Sweden	2016
Prasanthi Malapati	Birla Institute of Technology and Science, India	2018

Post-Doctoral Fellows

David Hajjar, Ph.D.
1977 - 1978

Michael Kinsella, Ph.D.
1980 - 1982

Renato Iozzo, M.D.
1982 - 1986

Sandra Harris-Hooker, Ph.D.
1981 - 1983

Eileen Bryant, Ph.D.
1984 - 1986

Sarah Bingel, D.V.M., Ph.D.
1984 - 1986

Michael Lark, Ph.D.
1985 - 1987

Tet-Kin Yeo, Ph.D.
1987 - 1989

Alan Snow, Ph.D.
1988 - 1991

Present Position

Professor of Pathology & Laboratory Medicine
Professor of Biochemistry
Dean of Graduate School
Weill Medical College, Cornell University
Cornell, NY

Research Associate Member
Benaroya Research Institute
Associate Professor of Pathology (Affiliate)
University of Washington
School of Medicine
Seattle, WA

Professor of Pathology
Director, Extracellular Matrix Program
Thomas Jefferson Medical School
Philadelphia, PA

Professor, Department of Pathology
Associate Dean, Research Development
Morehouse School of Medicine
Atlanta, GA

Director, Cytogenetics Laboratory
Fred Hutchinson Cancer Research Center
Seattle, WA

Associate Professor
Division of Laboratory Animal Resources
Medical University of South Carolina
Charleston, SC

CSO and Senior Vice President, Research
Trevena, Inc.
King of Prussia, PA

Research Assistant Professor
Department of Medicine (Clinical Pharmacology)
Dartmouth Medical School
Lebanon, NH

President & CSO
Proteotech, Inc.
Redmond, WA

Post-Doctoral Fellows - continued**Present Position**

Elke Schönherr, M.D., Ph.D. (deceased)
1988 - 1991

Associate Professor
University of Wales
Cardiff, Wales

Hannu Järveläinen, M.D., Ph.D.
1988 - 1991

Associate Professor
University of Turku
School of Medicine
Turku, Finland

Sandra Juul, M.D.
1990 - 1992

Professor
Department of Pediatrics
University of Washington
Seattle, Washington

Seppo Nikkari, M.D., Ph.D.
1992 - 1994
(shared)

Professor
Department of Medical Biochemistry
University of Tampere
Finland

Stephen Evanko, Ph.D.
1993 - present

Staff Scientist
Benaroya Research Institute
Seattle, Washington

Luiz Cardoso, Ph.D.
1995 - 1997

Scientist
University of Rio de Janeiro
Brazil

Mary Chang, Ph.D.
1996 - 1998
(shared)

Lecturer
Department of Comparative Medicine
University of Washington
Seattle, Washington

Joan Lemire, Ph.D.
1994 - 1997

Research Associate
Department of Biology
Tufts University School of Medicine
Boston, Massachusetts

Katherine Olin, Ph.D.
1998 - 2002
(shared)

Staff Scientist
Zymogenetics
Seattle, Washington

Lisa Tannock, M.D.
1999 - 2003
(shared)

Associate Professor & Chief
Division of Endocrinology and Molecular Medicine
Associate Director
Barnstable Brown Diabetes and Obesity Center
University of Kentucky
Louisville, Kentucky

Post-Doctoral Fellows - continued

Pamela Johnson, Ph.D.
1997 - 2002

Present Position

Staff Scientist & Histology Core Manager
Benaroya Research Institute
Seattle, Washington

Tom S. Wilkinson, Ph.D.
2001 - 2004

Associate Professor
Microbiology and Infectious Diseases
Institute of Life Science
Chair of Higher Degrees in the College of Medicine
College of Medicine, Swansea University
Swansea, Wales

Sana Sakr, Ph.D.
2001 - 2005

Research Scientist/Engineer 2
Comparative Medicine
University of Washington
Seattle, Washington

Rebecca Hull, Ph.D.
2001 - 2004
(shared)

Research Associate Professor
Metabolism, Endocrinology, & Nutrition
Department of Medicine
VA Puget Sound Health Care System &
University of Washington
Seattle, Washington

Marsha Rolle, Ph.D.
2004 - 2007

Associate Professor
Biomedical Engineering
Worcester Polytechnic Institute
Worcester, MA

Masanari Obika, M.D. (deceased)
2007 - 2009

Molecular Biology and Biochemistry
Graduate School of Medicine, Dentistry and
Pharmaceutical Science
Okayama University Medical School
Okayama, Japan

Inkyung Kang, Ph.D.
2008 - 2012

Staff Scientist
Benaroya Research Institute
Seattle, Washington

Andrew G. Ayars, MD
2010 - 2012

Assistant Professor
Allergy & Infectious Diseases
School of Medicine
University of Washington
Seattle, Washington

Post-Doctoral Fellows - continued

Nadine Nagy, Ph.D.
2011 - 2014

Present Position

Postdoctoral Fellow
Stanford University
Stanford, California

Gernot Kaber, Ph.D.
2011 - 2014

Postdoctoral Fellow
Stanford University
Stanford, California

Stephen R. Reeves, MD, PhD
2015 - present

Postdoctoral Fellow
Assistant Professor, Department of Pediatrics
Division of Pulmonary and Sleep Medicine
University of Washington, School of Medicine
Seattle, Washington

Visiting Scientists

Kuofen Chen, M.D.
1982 - 1983

Present Position

Professor of Cardiology (Retired)
Fu Wai Hospital
Beijing, China

Bertram Levy, M.D.
1989 - 1990

Practicing Urologist
Port Townsend, WA
Affiliate Professor of Urology
University of Washington
School of Medicine
Seattle, WA

Jens W. Fischer, Ph.D.
1996 - 1999

Professor
Department of Molecular Pharmacology
University of Dusseldorf
Dusseldorf, Germany

Merv Merrilees, Ph.D.
1998 - 1999
2006, 2008

Associate Professor
Department of Anatomy
University of Auckland
Auckland, New Zealand

Toshiyuki Kaji, Ph.D.
1998

Associate Professor
Department of Pharmaceutical Sciences
Hokuriku University
Kanazawa, Japan

Robert Hurst, Ph.D.
1999

Professor
Department of Urology
University of Oklahoma
Oklahoma City, OK

Visiting Scientists - continued

Hannu Järveläinen, M.D., Ph.D.
2000 - 2001

Associate Professor
Department of Medicine & Medical Biochemistry
School of Medicine
University of Turku
Turku, Finland

Jin-Yong Hwang, M.D.
2001 - 2002

Assistant Professor
Department of Internal Medicine
Gyeong-Sang National University
Hospital and College of Medicine
Jinju, Korea

Yann Gouëffic, M.D.
2002 - 2003

Assistant Professor
Department of Vascular Surgery
University Hospital of Nantes
France

Peter Little, Ph.D.
2002

Professor of Pharmacy
Head and Program Leader of RMIT Pharmacy
School of Medical Sciences
RMIT University
Bundoora, Victoria
Australia

Shigeshi Kamikawa, MD, PhD
2009

Practicing Cardiologist
Okayama Heart Clinic
Okayama, Japan

RESEARCH AWARDS

<u>Year/s</u>	<u>Title</u>	<u>(Role on Grant)</u>	<u>Annual Direct Costs</u>
1978 - 1979	Basil O'Connor Starter Research Grant March of Dimes	(PI)	\$14,165
1979 - 1981	March of Dimes Basic Research Grant	(PI)	\$22,000
1980 - 1982	NIH - NHLBI Vasoactive Agents PI: Gary Striker	(Co Investigator)	\$74,283
1979 - 1981	Sea Grant Carrageenan Effects	(PI)	\$19,600
1981 - 1983	R01: Endothelial Injury PI: Alexander Clowes	(Co-PI)	\$72,000
1979 - 1985	Reynolds Industries Program PI: Russell Ross	(Subproject PI)	\$22,070
1980 - 1985	NHLBI Program Project PI: R. Ross	(Subproject PI)	\$68,000
1981 - 1986	AHA Established Investigator Award	(PI)	\$30,000
1981 - 1985	AHA Grant In Aid	(PI)	\$33,000
1982 - 1985	NHLBI R01 Grant PI: Russell Ross	(Co PI)	\$80,841
1982 - 1984	Poncin Award	(PI)	\$3,600
1983 - 1985	NIADDK: R01 Proteoglycans in Chondrodystrophy	(PI)	\$71,000
1986 - 1987	Reynolds Industries Program PI: Russell Ross	(Subproject PI)	\$36,930
1985 - 1991	NHLBI Program Project PI: Russell Ross	(Subproject PI)	\$132,548
1985 - 1991	NHLBI Program Project PI: Russell Ross	(Core PI)	\$79,298
1986 - 1991	NIH Program Project in Dermatology PI: George Odland	(Subproject PI)	\$81,277

RESEARCH AWARDS - Continued

1987 - 1992	Research Center in Oral Biology PI: R. Page (Subproject PI)	\$124,320
1987 - 1988	Alzheimer's Disease Research Center Pilot Project: University of Washington PI: George Martin (Subproject PI)	\$5,000
1987 - 1988	Alzheimer's Disease and Related Disorders, Inc. (Pilot Project PI)	\$20,000
1988 - 1990	American Health Association Alzheimer's Disease PI: A. Snow (Co-PI)	\$50,000
1990 - 1995	NIH Program Project - Biology of the Artery Wall PI: Russell Ross (PI: Project 7)	\$186,017
1990 - 1995	NIH Program Project - Biology of the Artery Wall PI: Russell Ross (PI: Morphology Core)	\$112,645
1990 - 1995	Alzheimer's Disease Research PI: A. Snow (Co-PI)	\$120,741
1992 - 1996	NIH (R01) IL-1 and Matrix Signaling PI: Eva Qwarnström (Co-Investigator)	\$90,480
1994 - 1996	Bayer AG: Lipoprotein Matrix Interactions (Co-PI)	\$250,000
1994 - 1997	NIH (R01): Air Pollutant Effects on Mediators in Lung Cells PI: D. Luchtel (Co-Investigator)	\$179,000
1996 - 1999	NIH (R01) Mechanism of Matrix IL-1 Signaling (PI)	\$105,109
1995 - 2000	NIH Program Project (R. Ross, PI) Proteoglycans, Glycosaminoglycans and Atherosclerosis (PI: Project 7)	\$176,617
1999 - 2000	Merck Industries: The effect of LTD4 and montelukast on extracellular matrix production by cultured airway cells (Co-Investigator)	\$50,000
2001 - 2002	Research Servier: Proteoglycans in Human Varicose Veins (PI)	\$100,583

RESEARCH AWARDS - Continued

2001 - 2002	Abbott Laboratories: Prevention of Aneurysms by Proteoglycan Gene Transfer (PI)	\$100,000
2002	GlaxoSmithKline: Effect of Fluticasone and Salmeterol on the Synthesis of Proteoglycans by Airway Smooth Muscle Cells (PI)	\$39,015
2003 - 2004	NIH Program Project (A. Chair, PI) Lipoprotein – Matrix Interaction in Diabetes “Pathobiology of Macrovascular Disease in Diabetes” (Co-Investigator)	\$107,790
1999 - 2004	NIH Lipoprotein Lipase Program Project (J. Albers, PI) “Lipoprotein Retention by Artery Wall Biglycan” (Co-Investigator)	\$22,858
2002 - 2004	GlaxoSmithKline: The Provisional Extracellular Matrix in Asthma: Possible Targets for Therapeutic Intervention (PI)	\$161,948
2000 - 2005	“Proteoglycans, Glycosaminoglycans and Atherosclerosis” NIH Program Project (John Harlan, PI) (PI: Project 7)	\$231,416
2002 - 2005	“The Use of Proteoglycan Genes to Engineer Vascular Tissue” NIH /HLBI Grant (PI)	\$154,715
2004 - 2005	National Science Foundation Engineering Research Center UWEB Sub Project, (B. Ratner, PI) “Construction of a Tissue Engineered Blood Vessel Using a Gene Therapy Approach” (PI)	\$61,758
2002 - 2007	Pathobiology of Macrovascular Disease in Diabetes NIH / NIDDK Program Project (A. Chait, PI) “Lipoprotein - Matrix Interactions in Diabetes” (Project 1, Co-Investigator)	\$62,850
2007 - 2008	Lung Extracellular Matrix (ECM) in Asthma: Alterations in Response to the R,R and S,S- Enantiomers of Formoterol Sepracor (T. Wight, Co-PI)	\$33,333
2007 - 2008	Pancreatic Islet Extracellular Matrix in Autoimmune Disease Cooperative Study Group for Autoimmune Disease Prevention (T. Wight, Project PI)	\$50,000

RESEARCH AWARDS - Continued

2006 - 2008	Micro-thickness Collagen Membranes in Tissue Engineering NIH / NIBIB (R. Vernon, PI) Co-Investigator, 15% effort	\$22,500
2006 - 2009	Matricellular Protein-regulated Macrophage Recruitment <i>via</i> Stabilin-1 and VEGF Receptor 1 AHA (T. Wight, PI)	\$60,000
2008 - 2009	Retention of Inflammatory Leukocytes by the Extracellular Matrix (ECM) in Asthma: Alterations in Response to the (R)- and S-Isomers of Albuterol Sepracor (T. Wight, Co-PI)	\$90,000
2008 - 2009	Antibody Interference with Versican-Dependent Leukocyte Adhesion Washington Research Foundation (T. Wight, PI)	\$25,000
2008 - 2010	HLA Susceptibility Genes in Rheumatoid Arthritis NIH / NIAMS (G. Nepom, PI) “Interaction and Activation of T Lymphocytes with Specific Components of the Extracellular Matrix” Project PI	\$100,000
2007 - 2009	The use of a Mouse Model of HGPS to Define the Influence of Lamin A Δ 50 Expression on Vascular Extracellular Matrix Production and the Development of Vascular Disease Progeria Research Foundation (T. Wight, PI)	\$30,000
2008 - 2009	Lung Extracellular Matrix in Asthma Merck (T. Wight, PI)	\$45,000
2004 - 2010	Regulation of Cell Function by Matricellular Hevin NIH/NCI (T. Wight)	\$197,634
2004 - 2010	Human Lipoprotein Pathophysiology (LPPG) NIH / NHLBI Program Project (J. Albers, PI) “Lipoprotein Proteoglycans Interaction” (Project 4, Co-Investigator)	\$25,448
2006 - 2011	Bioengineered Allogeneic Tissue (BEAT) NIH / NHLBI (B. Ratner, PI) Lead Investigator	\$100,805

RESEARCH AWARDS - Continued

2006 - 2011	Biology of the Artery Wall and Atherosclerosis NIH / NHLBI (J. Harlan, PI) “Pro-inflammatory ECM: Key roles for Hyaluronan & Versican” Project 5, Principal Investigator	\$248,950
2008 - 2012	Center for Control of Inflammation & Tissue Repair DOD (M. Allen, PI) “Engineered Tissue Replacement Parts” Major Project 2, Principal Investigator	\$130,354
2008 - 2009	NIH/NIAMS BIRT Revision (G. Nepom, PI) “Interaction and Activation of T Lymphocytes with Specific Components of the Extracellular Matrix” Role: Project PI	\$100,000
2008 - 2013	Pathobiology of Macrovascular Disease in Diabetes <i>(Diabetes Program Project)</i> NHLBI/NIH (A. Chait, PI) Co-Investigator	\$21,919
2010 - 2012	Extracellular matrix involvement in type 1 diabetes pancreatic islet destruction JDRF (T. Wight, PI)	\$63,636
2010 - 2012	Gene-targeted mouse models to study the function of versican NIH / NCRR (C. Frevert, PI) Role: Co-Investigator	\$33,747
2011 - 2013	Targeting the Extracellular Matrix to Inhibit Saphenous Vein Graft (SVG) failure NIH / NHLBI (T. Wight, PI)	\$294,845
2013 - 2014	A Novel Role for Lymph Node Extracellular Matrix in Type 1 Diabetes Pathogenesis NIH/NIAID (J. Buckner, PI) Pilot Project PI	\$50,000
2010 - 2015	Regulation of pulmonary inflammation by leukocytes and extracellular matrix NIH / NHLBI (S. Ziegler, PI) <i>Versican: A Key Extracellular Matrix Regulator of the Innate Immune Response to Lung Infections</i> Project 1, PI	\$329,322
2011 - 2015	Engineering vascular replacements for strength and elasticity NIH / NIBIB (R. Vernon & T. Wight, PIs)	\$322,874

RESEARCH AWARDS - Continued

2014 - 2015	CSGADP Innovative Project – Pilot Project NIH/NIAID (J. Buckner, PI) Versican expression as an indicator of monocyte activation in diabetes Pilot Project PI	\$75,000
2012 - 2017	Extracellular matrix and immune regulation in autoimmune diabetes NIH / NIAID / NIDDK (P. Bollyky, PI) Co-Investigator	\$250,000
2015 - 2015	Dysregulated Airway Epithelial Signaling as a Driver of Airway Remodeling in Asthmatic Children NIH / NHLBI (J. Debley, PI) Subcontract PI	\$65,000
2015 - 2016	Extracellular matrix in the pathogenesis of human type 1 diabetes The Helmsley Charitable Trust (M. Bogdani, PI) George S. Eisenbarth nPOD Award for Team Science Co-Investigator	\$65,000
2015 - 2016	The pathogenic nature of the extracellular matrix in rheumatoid arthritis CSGADP, NIAID / NIH (J. Buckner, PI) Pilot Project PI	\$75,000
2016 - 2021	Epithelial regulation of the immune response to allergen sensitization and viral exacerbation NIH / NIAID (S. Ziegler, PI) Project 1: Epithelial regulation of ECM and leukocyte adhesion in viral-triggered asthma Co-Investigator	\$72,244
2016 - 2019	Dysregulated airway epithelial signaling as a driver of airway remodeling in asthmatic children NIH / NHLBI (J. Debley, PI) Co-Investigator	\$65,000
2017 - 2018	Inflammatory Roles of Hyaluronan- and Versican-Enriched ECM of the Joint Synovium from Rheumatoid Arthritis Compared to Osteoarthritis Patients Internal Funding (K. MacDonald, PI) Co-Investigator	\$40,000

RESEARCH AWARDS - Continued

2017 - 2018	Investigating Extracellular Matrix and Inflammation in Pelvic Floor Disorders Internal Funding Co-Investigator	(U. Lee, PI)	\$40,000
2018 - 2019	Extracellular matrix-NK cell interactions in T1D ITHS - Univ. Washington Co-Investigator	(A. Long, PI)	\$24,999
2018 - 2023	Lymph Node Extracellular Matrix in Antigen Presentation and Immune Regulation NIH / NIDDK Subcontract PI	(P. Bollyky, PI)	\$150,000
2019 – 2024	Regulation of Allergen-Induced Airway Pathophysiology by Versican NIH / NIAID Subcontract PI	(C. Frevert, PI)	\$92,000

PATENTS**Therapeutic Compounds and Methods**

Thomas N. Wight, Mervyn Merrilees

US Patent No. 7,816,335 issued October 19, 2010

European Patent No. 1274726 issued December 23, 2009

Australian Patent No. 2001253408 issued August 2, 2007

Australian Patent No. 2007203105 issued March 29, 2012

Methods for Promoting Elastogenesis and Elastin Fiber Formation by Increasing Tropoelastin Expression (BRI)

US Patent No. 8,367,619 issued February 5, 2013

Inhibition of Versican with siRNA and other Molecules (BRI)

Thomas N. Wight, Mervyn Merrilees

US Patent No. 8,410,067 issued April 2, 2013

4-Methylumbelliferone Treatment for Immune Modulation

Paul L. Bollyky, Nadine Nagy, Thomas Wight, Hedwich F. Kuipers

US Patent No. 10,285,976 issued May 14, 2019